University of Nebraska Medical Center

DigitalCommons@UNMC
Theses & Dissertations

Graduate Studies

Spring 5-4-2019

Molecular Mechanisms Governing Muscle Wasting in Cancer
Aneesha Dasgupta
University of Nebraska Medical Center

Follow this and additional works at: https://digitalcommons.unmc.edu/etd
Part of the Cancer Biology Commons

Recommended Citation
Dasgupta, Aneesha, "Molecular Mechanisms Governing Muscle Wasting in Cancer" (2019). Theses &
Dissertations. 366.
https://digitalcommons.unmc.edu/etd/366

This Dissertation is brought to you for free and open access by the Graduate Studies at DigitalCommons@UNMC. It
has been accepted for inclusion in Theses & Dissertations by an authorized administrator of
DigitalCommons@UNMC. For more information, please contact digitalcommons@unmc.edu.

Molecular Mechanisms Governing Muscle Wasting in Cancer

By
Aneesha Dasgupta

A Dissertation
Presented to the Faculty of Nebraska Graduate College
in Partial Fulfillment for the Requirements of
the Degree of Doctor of Philosophy

Biochemistry and Molecular Biology Graduate Program
Under the Supervision of Dr. Pankaj K. Singh
April 2019

Supervisory Committee Members

Dr. Angie Rizzino, Ph.D.

Dr. Keith Johnson, Ph.D.

Dr. Melissa Teoh-Fitzgerald, Ph.D.

Dr. Pi-Wan Cheng, Ph.D.

i

Dedicated to my parents and brother who never laughed at my dreams.
And to my grandparents and forefathers without whose genes, I wouldn’t have started on
this journey.

~

ii

Acknowledgement
I am grateful to my Ph.D. mentor, Dr. Pankaj K. Singh. He has been responsible
in inspiring, motivating and guiding me through my entire PhD journey. He has
made me the best version of the graduate student that I could be. All the accolades
and the awards that I have received in these last four years is due to his investment
in me. He was able to instill the same amount of ambition, drive and motivation in
me, which he has, for science and for making a difference. He has always asked
me to look at grander scheme of events. We have not always agreed with each
other, but he has always supported me when I needed him to. I have learnt a lot
from him and I would like to thank him for contributing his time and effort in building
my scientific acumen.
I would also like to thank all the past and current lab members. Each of them
has contributed to my scientific journey. I would like to start by thanking Dr.
Surendra K. Shukla. He has guided and taught me most of my skills that I attained
in the study of cancer cachexia. He has always been available to answer all my
questions and confusions and to oversee my experiments. I would like to thank Dr.
Enza Vernucci, for being a constant inspiration to me in the lab and to teach me to
keep working hard through all the frustrations and the failures. My time in the PhD
program would not have been half as enjoyable and fulfilling without her beside
me. I would also like to thank Dr. Jaime Abrego, Ryan King and Scott Mulder, who
are not just my fellow graduate students, but have eventually become few of my
best friends. These are the people with whom I have spent each day for the last 5
years. They have always helped me in dealing with large groups of mice surgeries,

iii

late night mice necropsies and any other help that I have ever needed. They have
been there through all the ups and downs in my PhD; we have celebrated the
sorrows and the joys of all our experiments together. I would also like to thank Dr.
Ravi Thakur with whom I have always had the most enlightening scientific
arguments. He has never hesitated to help me or to answer my questions. This
section is incomplete without mentioning Nina Chaika. I would like to thank her for
being patient with me since the first year and to help me whenever I needed her.
Somehow, she always had answers to all my technical struggles. My lab members
would agree when I say that the lab would not be held together without her constant
efforts.
I am immensely grateful to my entire supervisory committee, Dr. Keith
Johnson, Dr. Angie Rizzino, Dr. Pi- Wan Cheng and Dr. Melissa Teoh-Fitzgerald.
They have been guiding me in my attempt to answer the scientific questions that I
was pursuing in my dissertation studies. Their inputs and feedback have made my
research stronger and richer. I have enjoyed the constructive criticism of my work
and I want to thank them for their contribution in making me a better scientist. I
would also like to thank Dr. Rebecca Deegan and Dr. Matthew Zimmerman for
helping me navigate through the ROS studies with deeper understanding. My
studies also wouldn’t have been complete without the help of our clinical
collaborators - Dr. Lyudmyla Berim, Dr. Mridula Krishnan and Dr. Lei Yu- all of
whom have contributed to my clinical insight into pancreatic cancer cachexia.
I would like to thank all my friends in Omaha, who became my second family
Especially, Shrey, Tanmay and Deep – without whom I wouldn’t have been the

iv

best version of myself. I would also like to thank - Aishwarya, Rajvi, Pravin,
Navneet, Keenan, Tayla and Nicole. Without them, these five years wouldn’t have
been as enjoyable as it has been. My closest friends back home in Delhi, IndiaSudipta, Pearl, Yachna, Eshan, Raghav and Avinash- have been my constant
pillars of support and have cheered me on all these years, irrespective of the
distance. All these people make me the person who I am today.
Lastly, I would like to express my never-ending gratitude to my entire family.
I always like to say that my parents gave me wings to fly but roots to stay grounded.
They have empowered me in every possible way and never told me something is
impossible for me to achieve. My brother, Arjun has been a constant strength for
me and has taught me to face everything with a smile and a calm mind. My
grandparents have always encouraged me to pursue my dreams in the face of
societal pressures, for which I am always grateful. I would like to end by thanking
my cousin Shonali, brother-in-law Joe, Uncle Scott, Aunt Santwana and Uncle
Jayanta who have been there for me in the States, when I have been far away
from home.
It took all these people and more for me to be able to finish this journey amid
frustrations and anxiety.
Aneesha Dasgupta, 2019.

v

Abstract
Molecular Mechanisms Governing Muscle Wasting in Cancer
Aneesha Dasgupta, Ph.D.
University of Nebraska Medical Center, 2019

Supervisor: Pankaj K. Singh, Ph.D.
Pancreatic cancer is the third-leading cause of cancer-related deaths in the United
States. About 80 percent of the pancreatic cancer patients suffer from cachexia
and, about one-third die due to complexities related to the syndrome. Cachexia
leads to a loss in body weight and cachectic patients are refractory to
chemotherapy. Despite recent advances, the mechanisms of pancreatic cancercachexia and the potential therapeutic interventions remain poorly evaluated.
Sirtuins represent a class of proteins that are regulated by metabolic
fluctuations in tissues. We observed a reduced expression of Sirt1 in spontaneous
PDAC mice muscles, human pancreatic cancer muscles, and myotubes treated by
cancer cell-conditioned media. We further observed that cancer cell-conditioned
media upregulated the NF-κB and FoxO transcription factor pathways. NF-κB
regulated the expression of NADPH Oxidase (Nox4) in cachectic muscles, thereby
increasing reactive oxygen species (ROS). We also observed a negative
correlation between Nox4 expression and muscle cross-sectional area in the
cachectic muscles of PDAC patients. Inducible genetic knockout of Nox4 gene in
muscles of tumor-bearing mice rescued the cachectic phenotype. Moreover,
pharmacological blockade of Nox4 activity was successful in attenuating loss in
body weight and muscle mass in tumor-bearing mice. Therefore, we concluded
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that the Sirt1-Nox4 axis plays an important role in the manifestation of pancreatic
cancer cachexia.
Studies have shown that chemotherapy in addition to tumor burden can
induce body weight loss in cancer patients. We performed a single-center
retrospective study of 162 patients at our institution by measuring muscle mass
among patients with a diagnosis of pancreatic cancer at initial diagnosis and eightweek follow up post treatment. We found a significant improvement in overall
survival and progression-free survival in patients with modest or no reduction in
skeletal muscle index after eight weeks of chemotherapy. Furthermore, we treated
mice with Gemcitabine and FOLFIRINOX, and observed a decrease in body
weight, gastrocnemius muscle weight, grip-strength, and rotarod performance. We
also observed an increase in chemotherapy-induced ROS in the mice. We
observed that utilizing BMX-001, a SOD mimetic rescued the decrease in body
weight, muscle weight, grip-strength, and rotarod performance in mice treated with
chemotherapy. BMX-001 was also successful in rescuing chemotherapy-induced
muscle wasting in tumor-bearing mice. We concluded that targeting ROS
production in skeletal muscles could prevent chemotherapy-induced muscle
wasting.
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Chapter 1: Introduction
(Note – The introduction is adapted from a review article which is under revision
for submission as of April 2019)

The word cachexia is derived from the Greek words, “Kakos” meaning bad and
“Hexis” meaning condition. It is a multifactorial syndrome leading to loss in body
weight and is associated with many diseases, majorly cancer, AIDS, tuberculosis,
and chronic obstructive pulmonary disorder. The diagnostic criteria for cachexia is
defined as 5% loss in body weight over a duration of six months or 2% loss in body
weight for those whose body mass index (BMI) is less than 20 kg/m 2. However,
this diagnostic criterion did not include the prognostic significance of weight loss in
patients who initially have a low, intermediate, and high BMI. In 2015, the
diagnostic criteria for cachexia was revised by the consensus group and is now
included in the international practice guidelines of the European Society for Clinical
Nutrition and Metabolism (ESPEN)1. The group demonstrated differences in
survival across five categories of BMI (< 20.0, 20.0 to 21.9, 22.0 to 24.9, 25.0 to
27.9, and 28.0 kg/m2) and five categories of percent weight loss (WL) (-2.5 to -5.9,
-6.0 to -10.9, -11.0 to -14.9, ≥ 15.0%, and weight stable (±2.4%). They observed
that weight-stable patients with BMI ≥ 25.0 kg/m2 (grade 0) had the longest survival
and percentage WL values associated with lower categories of BMI were related
to shorter survival1.
Cachexia differs from starvation in the way that the weight loss is due to
depletion in adipose tissues and skeletal muscle mass but not non-muscle
protein2. Moreover, cachexia also differs from anorexia in the way that the loss in
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muscle and adipose deposits cannot be reversed by conventional nutritional
support and thus leads to progressive functional impairment3.
Previous studies have shown that cachexia is responsible for about 20% of
deaths of cancer patients4, although this percentage varies with the tumor type,
with an incidence of about 80% in pancreatic cancer patients, 40 to 50% in lung,
prostate and colon cancer patients5,6
The severity of cancer cachexia is inversely related to the survival of the
patient and it almost always leads to a poor prognosis. The main characteristics of
cancer cachexia is asthenia or lack of muscular strength. This entails the muscle
wastage as well as physical and mental fatigue. Along with it, loss in mean body
mass is the other trend in cachexia. It has also been observed that along with loss
in skeletal muscle, loss in cardiac muscle also occurs in cancer cachectic patients.
This might be a major reason of death in cachectic patients. The onset of cachexia
significantly influences the course of the disease. Furthermore, most anti-tumor
therapies also lead to muscle wasting and exacerbate the condition 7. Body weight
loss negatively influences survival by prevention of completion of chemotherapy.
Cachexia affects the metabolism of the entire host body as it affects multiple
organs. The severity of cachexia has been difficult to assess objectively and only
recently a method to stage cachexia has been validated8.
1. Diagnostic Techniques
Cachexia is typically diagnosed if a patient has lost 5% of their body weight over a
duration of 6 months or 2% of their body weight for those with a BMI of less than
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20 kg/m2. Moreover, though none of them are in clinical use yet, there are several
potential biomarkers which may be used to identify patients even before they show
signs of cachexia or weight loss. Plasma levels of ghrelin, leptin and adiponectin
have been found to be significantly higher in cachectic gastric cancer patients as
compared to non-cachectic gastric cancer patients9. Moreover, the plasma levels
of c-reactive protein (CRP) has been shown to be increased in the plasma of
cachectic cancer patients10.
A computed topography (CT) scan at the lumbar vertebrae level 3-4 is also
being utilized to measure skeletal muscle mass, which can detect small changes
and can be used to diagnose cachexia. Skeletal muscle can be identified around
the L3 and then demarcated and quantified based on preestablished Hounsfield
units (HU). Patients can be compared directly based on the measurements around
the lumbar region which can be correlated to whole body skeletal muscle 11,12.
Magnetic resonance imaging, appendicular skeletal muscle index from dual
energy x-ray imaging (DEXA) , mid-upper arm muscle area by anthrophometry and
whole body fat-free mass index by bioimpedence analysis are other methods to
assess cachexia in cancer patients3,13,14.
2. Cachexia Targets
Cancer associated cachexia in patients affects more than just the skeletal
muscles and the adipose tissues. It manifests effects on the whole body and
alters the functioning and signaling in the organs/tissues (Figure 1).
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a. Skeletal Muscle
In almost all cancers, muscle and weight loss is correlated with poor prognosis,
increased risk of treatment-related toxicity, and poor quality of life15,16. Additionally,
preventing muscle wasting can directly improve survival in tumor-bearing mice17.
Skeletal muscles comprise about 40% of the body weight and represent major
protein reservoir of the body. Skeletal muscles not only provide strength and
movement for the body, but also aid in maintaining posture and regulating body
temperature. The major cause of weakness and fatigue in cachectic patients is
muscle wasting18. The molecular basis of cancer-related muscle wasting is not fully
understood. Majority of the evidence suggest an impairment in synthesis and
degradation of protein and amino acid metabolism 4. Protein degradation in the
muscles is mainly mediated by the activation of the ubiquitin-dependent
proteasome pathway19. However, calpain-dependent cleavage of myofibrils, which
also leads to muscle wasting, acts upstream to the proteasome-dependent
degradation20. Furthermore, autophagy also plays a role in protein degradation 21.
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Figure 1 : Cachexia is a multifactorial syndrome which affects the whole
body.
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b. Cardiac Muscle
Cardiac atrophy is characterized by decreased heart mass mainly due to the
combination of decreased cell size and increased apoptosis 22. Cancer as well as,
anti-cancer therapies lead to cardiac atrophy which leads to functional impairment
of heart function. It leads to the increased burden of clinical symptoms such as
increased breathlessness, lethargies and sometimes cardiac arrest, leading to
mortality23,24. A study conducted by Mamidanna et al. demonstrated that about
25.4% of colorectal patient died due to cardiac causes25. Another study comprising
of 500 cancer patients, including gastrointestinal cancer patients, has shown that
cardiovascular peptides (N-terminal pro BNP-N-proBNP, mid-regional pro-atrial
natriuretic peptide-MR-proANP, mid-regional pro-adrenomedullin-MRproADM, cterminal pro-endothelin-1-CT-proET-1, copeptin) were upregulated in tumorbearing patients. Cardiopeptides concentrations were significantly correlated with
mortality independent of age, sex and tumor stage 26. Recently, a study including
pancreatic cancer, lung cancer and gastrointestinal cancer patients along with
healthy controls has demonstrated that body weight loss in these patients was
accompanied with loss of heart weight27.
Cancer-associated cardiac cachexia may be the direct consequence of
underlying heart disease, tumor burden itself or due to the chemotherapy,
unfortunately, the detailed molecular mechanism is not well explored 23. Cancerassociated cardiac cachexia patients exhibit reduced cardiac functions such as left
ventricular ejection fraction (LVEF), right ventricular ejection fraction (RVEF) and
morphological alterations such as interventricular septum thickness and posterior
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wall thickness28. Increased level of several cardiac peptides has been reported in
cancer patients. Increased level of BNP-NT-proBNP, MR-proANP, MRproADM,
and CT-proET-1 were found to be correlated with survival of cancer patients 26.
Altered organization of myofibrillar proteins, disrupted and degenerated sarcomere
has been observed in preclinical models of cancer-associated cachexia28. By
utilizing C-26 cancer-associated cachexia model, Wysong et al. have shown that
NF-κB inhibition exhibits cardio protective effect in tumor-bearing mice29.

c. Adipose Tissue
Cancer cachexia also entails a significant loss of white adipose tissue, which is
attributed to an increase in lipolysis rather than a decrease in lipogenesis 30,31.
Inhibiting lipid mobilization rescued cancer-induced cachexia in mice models32.
Although according to the 2011 consensus, skeletal muscle loss was a necessity
for the clinical diagnosis of cancer-associated cachexia, there has been evidence
that lipid wasting may occur before muscle wasting33,32. Therefore, the 2014
consensus which is based on initial BMI and percentage weight loss might be a
more accurate method to grade cachexia.
Cachectic patients with gastrointestinal cancer have elevated levels of
circulating free-fatty acids, triacylglycerol, and glycerol34. These fatty acids can be
taken up by skeletal muscles and high intramuscular fatty acids can induce the
expression of the ubiquitin ligases (Atrogin-1 and MuRF-1), leading to skeletal
muscle atrophy35. This study was further validated by the correlation of lipid
droplets in muscles of cancer patients with the extent of body weight loss 36. A
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recent study also demonstrated architectural modification consisting of fibrosis and
immune cell infiltration in the subcutaneous adipose tissues in gastrointestinal
cancer patients37.
Another interesting phenomenon of adipose metabolism in cancer
associated cachexia is the “browning” of white adipose tissue (WAT) , known as
brown fat35,38. These adipocytes have high mitochondrial content and increased
expression of the uncoupling-1 protein (UCP-1) and function like brown
adipocytes39. UCP-1 is responsible for uncoupling the mitochondrial electron chain
from ATP synthesis to thermogenesis40. In 2014, Petruzzi et al demonstrated that
WAT browning is an early event and increases systemic energy expenditure in
preclinical models of cancer-induced cachexia41. Another group demonstrated that
upon using a genetically engineered mouse model that have reduced thermogenic
potential and are resistant to browning, tumor-induced adipose tissue wasting was
significantly inhibited38. Interestingly, a recent study has demonstrated that
succinate can be metabolized by adipocytes and can induce thermogenesis,
implying a metabolic control of this process42.
d. Gut
Studies have demonstrated that cachectic mice with colon cancer (APC min/+)
undergo gut barrier disruption, which leads to increased systemic inflammation and
plasma endotoxin concentrations43. Moreover, gut microbiota affects the host
metabolism and immunity, two characteristics of the pathophysiology of cachexia.
Klebsiella oxytoca is increased in cachectic C-26 bearing mice and alters the gut
barrier function44. Lipopolysaccharide-binding protein, mostly associated with
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bacterial load, was increased in cachectic lung and colon cancer patients45. These
levels were also correlated with the serum IL-6 levels. Lipopolysaccharides, which
are pro-inflammatory compounds, can induce muscle wasting through the toll-like
receptor by activating the ubiquitin proteasome pathway and the autophagy
lysosome pathway46. Currently, the therapeutic potential of targeting gut
microbiota is being examined by administering prebiotics and probiotics. For
example, adding the bacteria L. reuturi to drinking water of mice with colon cancer
has been reported to lead to significantly increased gastrocnemius muscles and a
statistically significant survival advantage compared to controls 43. This suggests
that cachexia may be inhibited by the introduction of advantageous bacteria.
e. Liver
The liver plays a key role in whole-body metabolism. In both the liver and skeletal
muscle, an opposing pattern of protein metabolism is observed. Muscle
degradation leads to mobilization of amino acids like alanine and glutamine; while
glutamine is taken up by the tumor as a nutrient source, alanine is taken up by the
liver to produce glucose by gluconeogenesis47. Cytokines have been shown to
regulate liver metabolism by sustaining changes in the hepatic APPR (Acute
Protein Phase Response). IL-6 is known to be the principal regulator of APPR in
human hepatocytes48. Activation of APPR in the liver leads to hypercatabolism
because it reprioritizes whole-body protein metabolism from skeletal muscles to
the generation of acute phase proteins49. Production of acute phase proteins by
the liver correlates with the mobilization of amino acids from the skeletal muscle,
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which leads to loss of lean body mass. Further, Moses et al. found elevated APPR
to correspond with decreased survival in pancreatic cancer patients 50.

3. Systemic Alterations in Cancer Cachexia
In this section, we will illustrate the systemic alterations in cancer cachexia,
which includes the inflammatory, immune and metabolic pathways (Figure 2).
3.1 Cytokines
A loss in muscle weight is caused by a decrease in protein synthesis and an
increase in protein degradation. The most studied cause of muscle degradation is
the activation of the ubiquitination pathway by pro-inflammatory cytokines (Figure
3). A multitude of cytokines including TNF-α, IL-6, IL-1 have been implicated in
inducing cachexia in gastrointestinal cancers51-53. The hormone “cachectin” was
discovered by Beutler et al as a lipoprotein lipase suppressing hormone 54 and was
demonstrated to have detrimental effects on skeletal muscles plasma membrane
potential55. Cachectin was then recognized to correspond to the same protein as
the human TNF-alpha56. Following that, Oliff in 1987 demonstrated that injecting
CHO cells producing cachectin/TNF-α in nude mice killed the mice faster as
compared to those in which the CHO cells did not secrete cachectin 57. Moreover,
it was also established that blockade of TNF-α with etanercept improved the
tolerability of chemotherapy in patients with refractory gastric cancer 58. TNF-α
demonstrated synergy with interferon-γ in decreasing the levels of myosin heavy
chain in cultured myotubes and muscles of C-26.
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Figure 2 : Alterations in whole body metabolism. Tumor regulates whole body
metabolism by releasing factors that affect the muscles, adipose deposits and the
liver. Skeletal muscles and adipose tissues in turn secrete nutrients (amino acids
and fatty acids) that feed the tumor. Liver associated CD68+ macrophages can
also secrete cytokines in cachexia. Decrease in neuropeptide Y in the brain can
lead to decrease in appetite which causes loss in body weight.
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bearing mice. This study also established that myosin heavy chain was a target of
the pro-cachectic factors59.
There was an increased level of circulating cytokines (IL-6, IL-α, TNF-α) in
the serum of colon and pancreatic cancer patients suggesting a network of
cytokines collectively promoting cachexia60. Elevated levels of IL-6 in serum of
pancreatic cancer patients was associated with decreased muscle mass and
severe fatigue51. Circulating levels of IL-6 also have been demonstrated to be
elevated in the plasma of spontaneous mouse models of colon cancer which led
to loss in body weight53. Another study by the same group also established that
deleting IL-6 not only abrogated cachexia but also led to reduced tumor burden in
the colon cancer mouse model61.
The myosin differentiation factor, MyoD1, which binds to the promoter of
myosin heavy chain is regulated by these cytokines. The cytokines TNF-α and IL6 activate the p38 MAPK and the NFκB pathways which are needed to upregulate
the E3 ligases MURF1 and MAFbx , which modulate breakdown of sarcomeres
and inhibition of protein synthesis62. MURF1 is responsible for modulating the
ubiquitination of the myosin heavy chain and other thick filaments 63,64. The MURF1
and MAFbx family of proteins are regulated by the Forkhead box proteins, namely
Foxo3, Foxo1 and Foxo465. Furthermore, it was also demonstrated that the
injection of double negative foxo in the skeletal muscles of mice before
implantation of tumor cells reduced the mRNA levels of MAFbx and MuRF1, further
inhibiting muscle atrophy during cancer cachexia66.
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Figure 3 : Cytokines regulate muscle wasting factors. Immune cells and tumor
cells can release cytokines which affects both the liver and the skeletal muscles.
This can induce acute phase protein response in the liver. Cytokines can also
induce the liver to release c-reactive protein (CRP) into the blood vessels. Cytokine
released from the liver can also stimulate proteolysis in the skeletal muscles via
the activation of NF-κB. Activation of NF-κB can induce the transcription of the
muscle specific ubiquitin ligases- muscle ring finger containing protein-1 [MURF1]
and muscle atrophy F box protein [MAFbx]. Amino acids like glutamine and alanine
can be exported to the tumor to be used as nutrients
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3.2. Myostatin
A TGF-β family member, myostatin has been implicated in inducing cachexia.
Genetic null mutations for myostatin in humans and animals demonstrated muscle
hypertrophy67,68. Myostatin is mainly synthesized and secreted from the skeletal
muscle cells and function via the activin type IIb (ActRIIB) receptor. Although the
exact mechanism is still unclear, studies suggest that there might be multiple
pathways that act by inhibiting AKT and thus the downstream TORC1 pathways
which promote protein synthesis69,70. Inhibition of ActRIIB prevented muscle
wasting and prolonged survival in C-26 colon tumor-bearing mice17. A myostatin
inhibitor, BYM338 is currently in the phase 2 trial for attenuating body weight loss
in stage III/IV pancreatic cancer patients (ClinicalTrials.gov. Clinical study of
BYM338 for the treatment of unintentional weight loss in patients with cancer of
the lung or the pancreas). A humanized anti-myostatin antibody, LY2495655 is the
phase 2 trial in combination with gemcitabine to evaluate its efficacy in improving
survival and lean body mass in patients having advanced or metastatic pancreatic
cancer. (ClinicalTrials.gov. A Phase 2 study of LY2495655 in participants with
pancreatic cancer).
3.3. Proteolysis Inducing Factor
Proteolysis inducing factor (PIF) is produced by murine and human tumors.
Immunohistochemistry has demonstrated the presence of PIF in the cytoplasm of
gastrointestinal cancers and a correlation was established between its expression,
detection in the urine and weight loss71. In another study, PIF was detected in 80%
of pancreatic cancer patients who suffered greater significant weight loss and had
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increased rate of weight loss than patients who didn’t have PIF in their urine 72. It
has been reported that this factor leads to increase in protein degradation and a
decrease in protein synthesis73. Interestingly, when PIF was isolated from the urine
of cancer patients including pancreatic and colon, and injected into mice, it led to
induction of cachexia, without reduction in food or water intake 74. Unlike the
cytokines mentioned previously, PIF can act on isolated skeletal muscle and can
generate a state of cachexia in non-tumor bearing model without a decrease in
food intake75. In addition, administration of PIF to normal mice upregulated the
ubiquitin proteosomal pathway, indicating this as one of the mechanisms of action
of PIF76. These results were also validated in cell culture conditions with murine
myotubes. In the murine myotubes, addition of PIF inhibited the inhibitor of NF-κB,
which is IκBα. This resulted in more NF-κB entering the nucleus and an increased
expression of the regulators of the ubiquitin- proteosomal proteolytic pathway77.
Moreover, activation of NADPH oxidases and reactive oxygen species (ROS) also
play a role in PIF-induced expression of ubiquitin-proteosomal pathway which
leads to muscle degradation78,79. Increased ROS again leads to the degradation
of IκBα, which releases NF-κB from its inactive state78.
Although there has been a lot of evidence of inflammatory pathways being
involved in cachexia in preclinical models, the clinical trials with anti-inflammatory
agents have not shown promising results.
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3.4. Insulin-like growth factor (IGF-1)
In recent years, the role played by insulin-like growth factor-1 (IGF-1) has been
evaluated in the context of cancer-cachexia. It has been established that IGF-1
stimulates muscle protein synthesis, differentiation and proliferation of satellite
cells80. It mainly acts on the PI3K pathway which activates the downstream targets
which are required for protein synthesis81. It was observed that rats bearing
Yoshida AH-130 ascites hepatoma suffered from muscle atrophy which was
associated with decreased IGF-expression in the skeletal muscle. As a suggested
adaptive mechanism, skeletal muscles also demonstrated an increase in the levels
of the IGF-1 receptor82. Moreover, muscle wasting was rescued by the
administration of insulin but not IGF-1, possibly due to its low bioavailability82. In a
separate study, mouse models of colon adenocarcinoma and hepatoma
demonstrated that the cachectic tumor-bearing mice had decreased mRNA levels
of IGF-1 in the skeletal muscles. However, there was no difference in the activation
of the PI3K pathway suggesting that some other pathways might be responsible
for IGF-1-induced muscle wasting83.
3.5. Oxidative Stress
Reactive oxygen species are highly unstable and short-lived molecules that play a
major role in signaling and physiological pathways. Increase in oxidative stress is
another characteristic of cachexia/anorexia. In rats bearing Yoshida AH-130
hepatoma, there was an increased levels of total protein carbonylation in the
cachectic skeletal muscles84. This increase in oxidative modification was not
compensated by an increase in the antioxidants, which might be a reason for
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increased oxidative stress in cancer-induced cachexia84,85. It has also been
reported that mice implanted with Chinese hamster ovary cells transfected with
TNF-α become cachectic and lead to an increase in oxidative stress and nitric
oxide synthase in the skeletal muscles. This lead to a decrease in the myosin
creatine kinase which is needed for muscle differentiation 86. Oxidative stress has
also been reported to activate NF-κB which regulates the ubiquitin proteasome
pathway87. Moreover, it has been demonstrated that hydrogen peroxide induces
ubiquitin conjugation to proteins through the transcriptional regulation of the E2
and E3 enzymes in mice C2C12 myotubes88. In 2007, Russell et al suggested that
PIF and angiotensin can upregulate the ubiquitin proteasome pathway by ROS
produced by nicotinamide adenine dinucleotide phosphate (NADPH) oxidases
(Nox) in murine myotubes79. In the skeletal muscles of cachectic tumor-bearing
mice (MAC-16), there was an increase in Nox4 which generates hydrogen
peroxide and a decrease in antioxidants such as glutathione peroxidases,
catalases and superoxide dismutases85.
3.6. Impaired regeneration of muscle fibers
Muscle atrophy can not only be associated with increased muscle proteolysis, but
also decreased muscle regeneration or differentiation. Expression of Pax7, a
marker of muscle satellite cells was demonstrated to be increased in the skeletal
muscles of C-26 bearing mice. Sustained expression of Pax7 results in muscle
progenitors being in a state of self-renewal which results in impaired differentiation
and inhibition of fusion. This is also indicated by decreased levels of MyoD, which
is a downstream target of Pax789. Moreover, adenovirus overexpression of MyoD
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in skeletal muscles of tumor-bearing mice rescued muscle wasting89. Pax7 was
also reported to be increased in the muscles of cachectic gastric cancer patients 90.
MyoD is also demonstrated to be inhibited by the pro-inflammatory cytokines such
as TNF-α via NF-κB signaling91.
3.7. Appetite and Adipose Tissue Loss
A major aspect of cancer patients is the loss in appetite, which in turn may lead to
anorexia. Studies have demonstrated that about 50% of patients confirm
irregularities in their food habits at diagnosis92. Anorexia is differentiated from
cachexia, in the way that in anorexia there is a decreased interest to eat which
may lead to decreased food intake. Cachexia is the loss of adipose and muscle
mass which leads to hypoalbuminemia and asthenia that limits patient’s physical
activity and inhibits protein synthesis93. Cachexia is dissimilar from starvation as
there is preservation of lean body mass in starvation. Cancer patients suffer from
both anorexia and cachexia, though the loss in body weight cannot be attributed
to decreased food intake. This was further validated by studies demonstrating
muscle wasting even in the presence of normal food intake94. Moreover, it has also
been observed that administration of food and nutrients are unable to reverse the
muscle wasting95.
Along with skeletal muscle wasting, cancer cachexia entails a significant
loss of white adipose tissues. This loss has been attributed to an increase in
lipolysis rather than a decrease in lipogenesis30,31. Cachectic patients with
gastrointestinal cancer have elevated levels of circulating free fatty acids, triacyl
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glycerol and glycerol34. Some studies have also implied the loss in WAT precedes
the loss in muscle mass33.
3.8. Adipokines
Leptin is one of the major hormones associated with appetite. It decreases food
intake and increases energy expenditure. It was the first hormone to be discovered
which is secreted from adipocytes. It can cross the blood-brain barrier96 and has
its receptors at the hypothalamus. Its receptors are also present peripherally at the
skeletal muscles, pancreatic islet cells, kidneys and some other tissues 97. Along
with adipocytes, leptin has also been observed to be secreted by the gastric and
epithelial tissues98. There have been conflicting reports on the serum level of leptin
in cachectic cancer patients. One study reported that serum leptin levels are
observed to be decreased in patients with gastric cancer as compared to the
normal healthy control but there was no significant difference in cachectic and noncachectic patients99. Another study demonstrated that cachectic gastric cancer
patients had significantly higher level of serum leptin than the non-cachectic
patients; and a negative correlation was found between leptin levels and BMI 9.
There is also a definite crosstalk between leptin signaling and inflammation.
During fasting, leptin levels decrease and then again increase during the
postprandial phase. When fasted hamsters were treated with TNF-α and IL-1, they
showed an increased levels of leptin mRNA in the adipose tissues 100. This increase
in leptin was correlated with a decline in food intake. The cross talk between the
leptin and the inflammation pathways have also been demonstrated in studies
wherein peripheral leptin administration caused hypothalamic inflammation and
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central injection of IL-1 receptor (IL-1r) antagonist inhibited the suppression of food
intake caused by central or peripheral injection of leptin101,102.
Another important hormone associated with cachexia is the adipokine
called adiponectin. Adiponectin is specifically released by adipose tissues. There
is an inverse correlation between adiponectin and obesity and levels of adiponectin
increases with weight loss103. Serum levels of adiponectin is increased in cachectic
colon cancer patients104. In contradiction, reports have also shown association of
low levels of adiponectin to increased risk of gastric cancer105. An explanation for
this might be that TNF-α inhibits the secretion of adiponectin from adipocytes106,107.
It has also been demonstrated that adiponectin is increased in the cases of cardiac
cachexia irrespective of the body mass index. Adiponectin regulates the activity of
ceramidase which removes acyl chains from ceramides. Ceramides are related to
inflammation and insulin resistance108. In other studies, administration of
adiponectin, increased the molecules which are involved in fatty acid transport and
energy consumption such as acyl-coA oxidase and uncoupling protein-292.These
molecular processes decreases the tissue triglyceride content in skeletal muscles.
3.9. Ghrelin
Ghrelin, a natural ligand for the growth hormone receptor secretagogue receptor
(GHS-R) that is produced in the fundus of the stomach, is another important that
plays a key role in cancer cachexia109. However, ghrelin is shown to stimulate food
intake and adiposity by a GH-independent mechanism110. Counterintuitively,
patients with cancer and cardiac cachexia have increased circulating
concentrations of ghrelin, perhaps due to negative energy balance 104,111. Even in
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such cases, ghrelin administration resulted in an increase in food intake 112,113.
Studies have also demonstrated that Ghrelin decreases serum levels of IL-6.
Considering the role of inflammation in cachexia, this might be another mechanism
by which ghrelin can improve cachexia. However, it is not clear if all these
hormones play critical roles in cachexia in tumors of different origins.
3.10. Neuronal Regulation
Cachexia is mostly also associated with decreased food intake and change in taste
perception4. These are characteristics of anorexia which worsens the
manifestation of cachexia. It has been reported that both orexigenic (appetitestimulating) and anorexigenic (appetite-suppressing) pathways are altered in
cancer patients114. Increase in cytokines can activate anorexigenic pathways and
inhibit orexigenic pathways leading to the decrease of neuropeptide Y and thus
decrease in appetitie114. The melanocortin system can also participate in the
process of muscle wasting. Thus, in a mouse model of colon cancer, melanocortin
receptor antagonist abrogated muscle depletion115.
3.11. Lipid Mobilizing Factor (LMF)/Zinc alpha 2 glycoprotein (ZAG)
The search for a tumor-secreting product having lipid mobilizing activity led to the
purification of a 43 kDa glycoprotein from the cachexia-inducing MAC16 tumor116.
Zinc α2 Glycoprotein (ZAG) acts as a lipid mobilizing factor and is overexpressed
in certain malignant tumors117. ZAG has been reported to be present in the urine
of cachectic pancreatic cancer patients but not non-cachectic cancer patients116.
Moreover, a study also established the possibility of utilizing serum levels of
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ZAG/LMF as a biomarker for pancreatic cancer cachexia. Expression of ZAG was
also observed more in pancreatic cancer tumors of cachectic patients than noncachectic patients upon immunohistochemical analysis118. LMF/ZAG can directly
activate adenylyl cyclase in a GTP dependent process; thereby inducing
lipolysis119. It has been shown that administration of ZAG to mice reduces body fat
and induces hormone sensitive lipase (HSL)120. In 2004, Trayhurn and colleagues
demonstrated that ZAG is also expressed in white adipose tissues (WAT) and is
observed to be overexpressed in adipocytes of MAC16-bearing cachectic mice
121.ZAG

is also expressed in brown adipose tissue (BAT) in cachectic mice, which

is required for lipid utilization121. Thus, BAT increases energy utilization by
generating heat instead of ATP in cachectic mice by upregulating BAT UCP1
mRNA, via ZAG.
3.12. Triglyceride Lipases
White adipose tissue (WAT) is the reservoir for triaclyglycerides (TAG). The TAGs
in the WATs are broken down by adipose triglyceride lipase (ATGL), in a rate
limiting step to form diacyl glycerides (DAGs). The DAGs are broken down by
hormone sensitive lipase (HSL) to form monoacylglycerols (MAGs), which is
further broken down into free fatty acids and glycerol by monoglyceride lipases
(MGL). Many factors regulate these lipases which lead to increase or decrease of
lipolysis. In cancer cachexia, there is evidence of decrease in TAGs in WAT rather
than complete cell death. The levels of HSL were reported to be two-fold higher in
the WAT of cancer patients as compared to the control group 122. HSL is activated
by its phosphorylation which is modulated by protein kinase A, extracellular signal-
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regulated kinase (ERK), glycogen synthase kinase 3β (GSK-3β; previously known
as GSK-4), calmodulin-dependent kinase II (CAMKII), as well as AMP-activated
protein kinase (AMPK)123,124. It was demonstrated that the ATGL activity is
increased in murine cachexia models with increase in tumor burden and WAT
mobilization32. ATGL knockout mice showed protection from tumor induced
lipolysis. Moreover, cachectic cancer patients showed significantly increased
ATGL activity in their WAT tissues32. In addition, ATGL is also observed to be
expressed in skeletal muscles and reported to play an important role in lipid
metabolism in muscles125. HSL activity and expression in skeletal muscles is also
reported to lead to insulin resistance126.
3.13. Insulin Resistance
Glucose intolerance was the first metabolic abnormality that was recorded in
cancer patients127. The main hormone to control blood glucose levels is insulin,
which plays a major role in whole body metabolism including fat, amino acid and
protein metabolism. Consumption of a meal triggers the release of insulin from
pancreatic beta cells which decreases circulating blood glucose levels. This
happens due to the action of insulin on muscles and fat deposits which makes
these tissues utilize glucose thereby decreasing its concentration in the blood.
In 1965, one of the earliest large scale studies to report metabolic effects of
cancer, including cancer of the GI tract, in patients demonstrated a significant
percentage of cancer patients suffering from glucose intolerance or diabetes 128. It
has been reported that there is a high incidence of glucose intolerance in
pancreatic cancer patients, which cannot be explained by impaired secretion of
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insulin129. Furthermore, it has also been demonstrated that insulin infusions into
skeletal muscle increases amino acid uptake and reduces proteolysis 130. Higher
doses of insulin infusions decrease the blood glucose levels but have no effect on
protein mass130 .Therefore, there is evidence that insulin affects skeletal muscle
mass and alterations in the levels of insulin can perturb proteolysis.
There has also been evidence regarding the development of glucose
intolerance before the manifestation of cancer. Norton and his colleagues
demonstrated that in 27 otherwise healthy patients with localized sarcoma, glucose
intolerance occurred before other signs of cachexia appeared 131. Furthermore, in
the said cohort, those patients who had less than ideal body weight showed lower
glucose tolerance than the other patients. These studies indicate the role of
glucose tolerance and insulin sensitivity in muscle wasting in cancer patients. Mice
bearing colon-C26 adenocarcinoma demonstrated a blunted blood glucose
response to insulin in an insulin tolerance test before a difference in body weight
was observed. This suggested that insulin resistance is an early event in the
development of cancer cachexia132. One of the factors identified for impaired
insulin signaling is TNF-α, which is observed to decrease the autophosphorylation
of the insulin receptor(IR) and the IR substrate 1133.
The insulin signaling pathway overlaps with the ubiquitin proteolytic
pathway. Insulin binding to its receptor activates the PI3K and AKT. AKT
suppresses FOXO3 and caspase-3 activation, thus decreasing the expression of
the muscle ubiquitin ligases atrogin-1 and murf-1. However, in cancer cachexia,
when patients suffer from insulin resistance, the suppression of PI3K and AKT is
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decreased and there is an increased expression of the components of the ubiquitin
proteolytic pathway. This is one mechanism through which insulin resistance can
control muscle degradation134. Insulin resistance might fuel tumor growth in two
possible ways – first, by promoting muscle wasting and thus mobilizing amino
acids into circulation; second by promoting liver gluconeogenesis135 which would
increase REE, tissue wasting and would fuel cancer aerobic glycolysis.
3.14. Fatty Acid Oxidation
Cancer cell-secreted inflammatory factors can lead to increased fatty acid
metabolism

and

p38

stress

signature

in

the

muscles 136.

Moreover,

pharmacological blockade of fatty acid oxidation improves muscle mass and body
weight in vivo136.
The metabolic capacity of skeletal muscles is a substantial characteristic in
the pathophysiology of cancer cachexia. Muscle fiber subtypes are traditionally
delineated by the isoform of myosin heavy chain (MHC) expressed (eg. slow
twitch- type I; fast twitch- type IIA, IIB, and IIX) that impacts the metabolic
phenotypes and mitochondrial capacity137. Myogenesis tends to alter the metabolic
profile from a glycolytic phenotype toward a greater dependency on oxidative
phosphorylation138. MHC subtype I and IIA containing isoforms most heavily rely
on oxidative metabolism, and MHC type IIB and IIX are highly glycolytic 139. The
rate of protein synthesis is greater in the oxidative muscle fibers as compared to
the glycolytic ones140. Of note, multiple mice models of cancer cachexia display
the loss of the oxidative phenotype141. Extrapolating this evidence, there are also
studies which demonstrate decreased protein synthesis in mouse models of
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cancer cachexia142. While it is not known if muscle wasting leads to changes in
MHC subtypes, metabolic profiling studies indicate decreased overall glycolytic
capacity.
3.15. Mitochondrial biogenesis and dynamics
Dynamic mitochondrial networks fulfill the energy demands of different cells and
play a very important role in cellular physiology. Due to the high energy demands
in muscles, mitochondria, the cellular energy factories, play a significant role in
muscle physiology and pathologies143. Dysregulation of mitochondrial biogenesis
and dynamics regulates muscle mass and physiology by regulating different
molecular and signaling events144,145. Recently, Brown et al., have shown that
mitochondrial degeneration precedes the muscle atrophy in murine models of
cancer-associated cachexia146. Several published studies and genome-wide
dataset analysis from different animal models of cancer-associated cachexia have
revealed altered expression of genes involved mitochondrial biogenesis and
dynamics147.
Skeletal muscles from cancer patients display significant alterations in the
expression of genes involved in mitochondrial dynamics. A study involving 18
patients of gastric adenocarcinoma (nine cachectic and nine non-cachectic) along
with 9 healthy controls, showed altered expression of mitochondrial dynamics
genes. Cachectic cancer patient muscles displayed reduced expression of FIS1
fission protein, and lipidated and non-lipidated forms of LC3B148. ApcMin/+ mouse
model of colon cancer-associated cachexia also displays altered expression of
proteins regulating mitochondrial dynamics, including PGC1-α and mitofusins
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(Mfn1, Mfn2), even before changes in mitochondrial mass are apparent at the early
stages of muscle wasting149. However, with the progression of the cachectic
phenotype these mice exhibit the loss of mitochondrial content with decreased
expression of PGC1-α and mitofusins, and increased expression of Fis1 149. C-26
tumor-bearing mice, another model of colon cancer-associated cachexia, present
reduced expression of PGC1-α, TFAM, and TOM20 in skeletal muscles, which
correlates well with the reduced cross-sectional area of gastrocnemius muscles
and increased expression of cachectic markers150. C-26 tumor-bearing mice
skeletal muscles also exhibit distorted mitochondria, impaired oxidative capacity,
and reduced ATP regeneration that may significantly impact the contractile
function and predispose the mice to muscle wasting151. Altered mitochondrial
biogenesis and dynamics leads to bioenergetic insufficiency and increased
oxidative stress due to generation of reactive oxygen species (ROS). Reduced
oxidative capacity, altered protein synthesis and membrane fluidity, and posttranslationally-modified

mitochondrial

proteins

altogether

hampers

the

mitochondrial function in cachectic muscles4. While a few preclinical cachexia
models have evaluated alterations in mitochondrial homeostasis, the broad scope
of mitochondrial biogenesis and dynamics in gastrointestinal cancer-associated
cachexia in patients is still underexplored. More clinical and preclinical studies
under

relevant

physiological

conditions

can

significantly

improve

our

understanding of the dynamic mitochondrial networks in cancer-associated
cachexia.
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3.16. Zinc Metabolism
Cachectic muscles in patients and animal models display significant accumulation
of zinc152. Animal models with fibrosarcoma, lewis lung carcinoma, and murineadenocarcinoma demonstrate accumulation of zinc in the cachectic skeletal
muscles153. Siren et al. hypothesized that though zinc homeostasis is normally
tightly regulated, during inflammation, infection, or cancer zinc dyshomeostasis
can occur via an acute phase protein response (APPR)152. Regarding the potential
mechanisms of zinc accumulation in cachectic muscles, zinc transporters are
induced in cachectic muscles. The cachectic cytokine IL-6 regulates the zinc
transporter (Zip14) in the liver which contributes to the hypozincemia during
APPR154. Furthermore, due to the critical role of zinc in immune regulation, altered
zinc metabolism can also contribute to systemic inflammation as observed in
cachexia155. Recently, Wang et al. also demonstrated an upregulation of ZIP14 in
the cachectic muscles of metastatic cancer models156. Transforming growth factor
beta (TGF-β) and TNF-α mediated the induction of ZIP14 expression in the
muscles of these models. ZIP14- mediated Zn accumulation also blocked muscle
differentiation, along with decreased levels of myosin heavy chain156.
4. Immunological aspects of GI cancer-induced cachexia
The immunological status of the host body is a major determinant in progression
of cancer and cachexia. Studies have demonstrated a strong decline in contact
hypersensitivity, a parameter for cell-mediated immunity, in C26 tumor-bearing
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cachectic mice157. Interestingly, this decline was observed even before the mice
underwent weight-loss, therefore implicating the importance of immunity in the precachectic state. Cachectic pancreatic cancer patients also had an increased
infiltration of activated macrophages in the liver as indicated by CD68
immunoreactivity158. The amount of IL-6 staining in hepatocytes surrounding the
CD68-positive macrophages was significantly increased in cachectic pancreatic
cancer patients as compared to non-cachectic patients, indicating that liver
parenchymal cells may be triggered by macrophages to produce pro-inflammatory
cytokines like IL-6158.
5. Chemotherapy-induced cachexia in gastrointestinal cancers
Anti-tumor cytotoxic agents have several deleterious impacts on normal tissues
and physiology159 (Table 1). Chemotherapeutic agents have been shown to exhibit
pro-inflammatory properties160,161 and deregulate nitrogen metabolism of the host
body162. Chemotherapeutic agents such as cisplatin, FOLFOX (5-FU, leucovorin,
oxaliplatin), FOLFIRINOX (5-FU, leucovorin, irinotecan) , doxorubicin and
sorafenib contribute to myopathy independent of their anti-tumor effect in
preclinical models of cancer-induced cachexia163,164,165,166,167. Recently it has also
been shown that muscle wasting is associated with long term use of mTOR
inhibitors168. In a longitudinal study of colorectal cancer patients with metastasis, it
was observed that muscle area decreased significantly during combination of
capecitabine plus oxaliplatin with or without bevacizumab treatment and it was
independently associated with survival in patients169. Similarly, Eriksson et al.,
have reported that muscle mass decreases during neoadjuvant chemotherapy in
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patients with resectable colorectal liver metastases170. Gemcitabine, the first line
standard of care for pancreatic cancer has been shown to induce muscle atrophy
in a mouse model of pancreatic cancer171.
Molecular mechanism of chemotherapy-induced muscle wasting varies
widely. Chemotherapy-induced alteration of ROS homeostasis plays important
role in muscle weakness and fatigue172. FOLFOX has been shown to induce
muscle atrophy by activating ERK1/2 and p38MAPKs signaling pathways in
addition to modulating mitochondrial biogenesis163. Widely used anti-cancer agent
doxorubicin induces muscle atrophy by altering calcium homeostasis of muscle
and inducing autophagy165,173. Doxorubicin also modulates TNF1R activity in
skeletal muscles174. Furthermore, it has been shown that doxorubicin treatment
results in hyperglycemia and insulin resistance which is mainly mediated by
negative regulation of AMPK signaling pathway in mice muscles175. Baretto et al.
have demonstrated that chemotherapy -induced muscle wasting and cancerinduced muscle atrophy share common alterations in signaling pathways 176.
Modulation of glucocorticoid receptor mediated signaling has been reported to play
an important role in 5-FU mediated muscle atrophy in murine skeletal muscles177.
Only a few pre-clinical studies have explored the therapeutic options to manage
chemotherapy-induced cachexia. It has been shown that ACVR2B/Fc prevents
FOLFRI mediated muscle loss178. Mirtazapine, an antidepressant drug has shown
to prevent gemcitabine-induced mild cachexia in mouse model of pancreatic
cancer171.
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Table 1 : Mechanisms of Muscle Wasting via Chemotherapy Drugs
Drug
Cisplatin

Folfox

Mechanism of Muscle Wasting
AKT Pathway Impairment
Increased Ubiquitin Proteasome and Autophagy
Pathway
Upregulation of FoxO1/3
ERK1/2 p38 MAPK
Modulation of glucocorticoid receptor

Doxorubicin

Calcium Homeostasis and Autophagy
Inhibition of AMPK

Sorafenib

Not known

Gemcitabine

Loss in Appetite
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6. Regulation of muscle atrophy by microRNAs
MicroRNAs (miRNAs) are short noncoding RNAs which play an important role in
post-transcriptional gene regulation, thus affecting several key biological
processes including muscle atrophy179. Recently Narsimnhan et al. have shown
that several miRNAs are differentially expressed in skeletal muscles of cachectic
verses non-cachectic pancreatic and colorectal cancer patients180. They observed
that miR-3184-3p, miR-1296-5p and let-7d were significantly upregulated in the
muscles of cachectic patients180. Moreover, it has been shown that miR-378
regulates lipolysis in gastrointestinal cancer patients181. Pancreatic tumor-derived
microvesicles containing miR-21 induces myotube atrophy by inducing apoptosis
through TLR activation182. miR-21 has been also shown to be upregulated in
denervation induced muscle atrophy and it regulates translational initiation
process183. Overall, these evidences suggest that several miRNAs regulate
muscle atrophy and lipolysis in gastrointestinal cancer-induced cachexia.
7. Serum Metabolic Profile
Recent studies have demonstrated distinct metabolic profiles in cachectic cancer
patients compared to non-cachectic cancer patients184. Cancer patients with
cachexia presented decreased glucose and elevated lactate in the serum,
compared to the non-cachectic ones. Metabolomic profiling identified 45
distinguishing metabolites and 18 metabolic pathways that were associated with
cachexia. Out of the 45 metabolites, logistic regression analysis revealed
diagnostic potential of a three-metabolite signature, consisting of carnosine,
phenylacetate, and leucine. Similar metabolic alterations have been observed in
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mice sera185. In addition to the metabolic changes observed in the serum
specimens, gastrocnemius muscle specimens from murine cancer cachexia
models also reflect metabolic changes associated with wasting185. Of note, that the
common metabolic changes between human and the murine model included
leucine, phenylacetate, and carnosine.
Another study utilizing a cohort of 390 cancer patients demonstrated that
49% of the patients had hypermetabolism which was associated with clinical and
biological features of precachexia186. Hypermetabolism also correlated with
decreased survival in metastatic cancer patients187.
8. Metabolic Alterations in the Tumor
Altered metabolism is a known hallmark of cancer cells (Figure 4). Under normal
conditions, metabolic pathways are highly regulated, but once the cells undergo
malignant transformation due to the induction of oncogenes or suppression of
tumor suppressors, tumor cells reprogram the metabolic pathways to need their
growing cellular requirements188. The metabolic pathways that majorly get
reprogramed is glycolysis, glutaminolysis and fatty acid synthesis. Recent studies
by our laboratory have demonstrated that pancreatic cancer patients on
chemotherapy who had a higher PET signal had poor prognosis, suggesting that
patients having higher glucose uptake, had poor survival189.
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Figure 4 : Metabolic alterations in tumor and serum. Metabolic alterations in
tumor, distinct uptake and release of metabolites from the tumor and its uptake in
the muscles regulate muscle wasting.
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Extrapolating this evidence, it can be hypothesized that different tumors can have
different metabolic alterations which can affect patient prognosis and survival.
Several reports have demonstrated that specific metabolite uptakes are required
for tumor progression, for example glutamine190, serine191, branched amino acids
and lipids192 in cancers including gastrointestinal cancers. Interestingly, in 2014
Mayers et al profiled the prediagnostic plasma metabolite levels of patients with
pancreatic cancer and observed an increased level of branched chain amino acids
as compared to the plasma of control cohorts193. This suggests that whole-body
protein break down occurs even before the cancer is diagnosed in patients.
Furthermore, Luo et al identified metabolic cross talk occurring between colorectal
cancer and skeletal muscles. It was demonstrated that colorectal tumors release
high-motility group box 1 (HMGB1) which leads to the metabolic reprogramming
of skeletal muscle through RAGE (Receptor for Advanced Glycation End-products)
by inducing autophagy and release of free amino acids in the plasma (Figure 5).
13C

tracing experiments confirmed the transfer of carbon skeleton from the

muscles to the tumor.
Cachexia has also been shown to be associated with hypoalbuminemia 194.
But this condition was shown to be independent of functional capacity of the liver
and, in turn, was said to be related to increased protein breakdown or increased
utilization of protein by the tumor. It was also demonstrated that insulin releasing
compounds, like glucose, failed to release insulin in cachectic rats195. This study,
along with their own, led Jasani and colleagues to conclude that in order to combat
cachexia it is not only essential to improve dietary protein intake but also reduce

36

the metabolic activity of the tumor tissue194. Since only protein replenishment has
served to be effective in non-malignant cachexia, combating the metabolic
activities of the tumor tissue is crucial.
9. Advances Made in Altering Metabolic Pathways
Cachexia, till date has no FDA approved therapies. In the clinic, cachexia is
managed by nutritional supplements or hormones to increase appetite. In research
labs, attempts are being made to evaluate compounds which can target the tumor
and combat muscle wasting (Figure 6).
a. Ketone Bodies and Fenofibrate
It has been demonstrated by Shukla et al in 2014 that a ketogenic diet leads to
diminished glucose flux in the pancreatic cancer cell lines196. This also reduced
glutamine uptake, ATP content and reduced survival in pancreatic cancer cell lines
while inducing apoptosis. The metabolic reprogramming of pancreatic cancer cell
lines reduced cachexia in the cell line model. This was further confirmed in mouse
xenograft models. Hence, following a ketogenic diet might be a successful strategy
to combat cachexia.
A unique metabolic gene signature in a murine model of cancer cachexia, which
involved losing the peroxisome proliferator-activated receptor-α (PPARα)dependent ketone production in the liver, was also reported197. There was a rise
of glucocorticoid levels which correlated with degeneration of muscle fibers and
increased hepatic gluconeogenesis. This loss in skeletal mass could be prevented
by restoring the ketone production by a PPARα agonist, fenofibrate197.
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Figure 5 : Tumor cells secrete factors which degrade skeletal muscles.
HMGB1 is released from the tumor cells and is shown to inhibit the conversion of
phosphoenolpyruvate (PEP) to pyruvate. This can inhibit the TCA cycle in
muscles. HMGB1 can also induce autophagy in muscles, which can increase
proteolysis leading to the generation of glutamine. Glutamine can be taken up by
tumors to generate glucose.
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b. Silibinin
Silibinin is a natural product which has been demonstrated to have anti-cancer
properties. Our lab demonstrated that silibinin successfully reduced the growth of
pancreatic cancer cells by reducing glycolytic flux198. Moreover, it was also
demonstrated that silibinin reduces tumor growth and proliferation in an orthotopic
mouse model of pancreatic cancer and prevents loss of body weight and muscle
mass.
c. Etomoxir
In recent studies, Fukawa and colleagues reported that factors released by
cachectic cancer cell lines induce fatty acid oxidation in human myotubes, which
lead to oxidative stress, p38 activation and impaired muscle growth 136. Moreover,
pharmacological blockade of fatty acid oxidation by administration of etoxomir not
only prevented human myotube degradation but also improved muscle mass in
murine models of cancer cachexia136.
d. Antioxidants
Since oxidative stress-induced modifications are an important part of muscle
wasting, antioxidants are being tested for their efficacy in combating cancercachexia. It was reported that D-alpha-tocopherol, an antioxidant was successful
in combating muscle wasting in a murine model of cancer cachexia by decreasing
the oxidative stress86.
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Figure 6 : Targeting tumor metabolism in order to combat cachexia. Tumor
metabolism can be altered by ketone bodies which inhibits glycolysis, by etoxomir
which blocks fatty acid oxidation or by silibinin which inhibits c-myc thereby
inhibiting transcription of glycolysis genes. Antioxidants can directly affect the
muscles by reducing reactive oxygen species related damage, which can then
inhibit the transcription of ubiquitin ligases.
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10. Potential for new therapeutic approaches
Although a lot is known about the mechanisms of cachexia development, most of
the therapies which includes anti-inflammatory drugs, nutrition support, hormonal
supplements have not given promising results in clinical trials199. As mentioned in
this chapter, because cachexia is a product of inflammatory and metabolic
alterations, a combination of drugs targeting both these pathways looks most
promising. Since chemotherapy can also aggravate muscle wasting, compounds
which combat muscle wasting can be administered along with chemotherapeutic
drugs to ameliorate the effect of chemotherapy on the muscles. This is not a trivial
pursuit since it is important to not decrease the efficacy of the chemotherapeutic
drug by its combination with chemoprotectant drugs.
11. Conclusion and Perspectives
It has been three decades since the discovery of “cachectin”, and yet there has
been no promising therapeutic approach to combat cachexia. As previously
mentioned, cachexia is more than just a wasting disease; it reduces the patient’s
ability to receive or respond to therapy and decreases survival. It is a multifactorial
syndrome that is associated with anorexia and hyper catabolism due to proinflammatory cytokines, hormones, neuronal peptides, tumor-derived factors and
altered tumor metabolism. A lot of research is still required to target these factors
together in a multimodal therapeutic approach. This is challenging since each
tumor varies genetically and metabolically and a common approach might not be
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effective for all patients. This suggests that there is a need for the development of
personalized medicine to combat cancer and also mitigate cachexia.
12. Goals of the Dissertation
The aim of this dissertation is to elucidate novel mechanisms involved in the
manifestation of pancreatic cancer-cachexia. To this end, we utilized spontaneous
pancreatic cancer mouse models, pancreatic cancer patient muscle samples and
in-vitro models of muscle atrophy. Chapters 3 and 4 illustrate the role of Sirt1-Nox4
axis in inducing cachexia and Chapter 5 investigates the role of chemotherapy in
muscle wasting in pancreatic cancer.

42

Chapter 2: Methods and Materials
All the chapters of this dissertation are majorly focused on methods involving
muscle wasting. Since most of the projects utilize similar methods, they are
described in this section:
Cell Culture and Reagents
Pancreatic cancer cell lines T3M4 and S2-013 were generous gifts from Dr.
Michael A. Hollingsworth200. Cell lines were validated by STR profiling by the
Genetics Core at Arizona University. Mouse pancreatic cancer cell lines (KPC
1245, 1199 and 242) were derived from the transgenic mice models described
below. Colon cancer cell line C26 was obtained from ATCC. All cell lines were
cultured in Dulbecco's Modified Eagle Medium (DMEM) (Sigma-Aldrich D5648)
with 10% fetal bovine serum (FBS), 100 I.U./ml penicillin, 100 μg/ml streptomycin,
and incubated at 37°C in a humidified incubator with 5% CO 2. C2C12 myoblasts
were obtained from ATCC and cultured in DMEM with 10% FBS until confluent.
After reaching confluency, the myoblasts were differentiated in DMEM with 2%
horse serum and 1 µg/ml insulin for 72 hours, as previously described 198.
Resveratrol for in-vitro studies was purchased from Sigma-Aldrich (R5010) and
stocks were diluted in DMSO. Ex-527 was purchased from Santa Cruz
Biotechnology (CAS 49843-98-3). NBD peptide / NF-κB blocker (ALX-163-011-1)
was purchased from Enzo Life Sciences. FoxO1 inhibitor, AS-1842856 (16761)
and Nox4 inhibitor, GKT 137831 (1218942218942-37-0) was purchased from
Cayman Chemical. BMX-001 was a kind gift from Dr. Rebecca Oberley-Deegan
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(UNMC). Leucovorin, Oxaliplatin, 5-fluoroplatin, Irinotecan and Gemcitabine were
purchased from Nebraska Medicine Pharmacy.
Lentivirus and Adenovirus Transfection
Cell transfections for producing replication-incompetent lentivirus were performed
by utilizing Turbofect (Thermo Scientific), following the manufacturer's protocol.
Stable short hairpin RNA (shRNA) constructs for Sirt1 were obtained from SigmaAldrich. After transfection, cells were selected using puromycin. Human NOX4
adenovirus was a kind gift from Dr. Melissa Teoh Fitzgerald (UNMC). GFP
adenovirus was a kind gift from Dr. Matthew Zimmerman (UNMC).
Mouse Sirt1 adenovirus was purchased from ABM (222151A). C2C12 myotubes
were differentiated for 48 hours following which, a MOI (multiplicity of infection) of
200 was used to transfect the myotubes.
Cancer Cell-conditioned Media Preparation
For conditioned medium (CM) preparation, S2-013 and T3M4 cell lines were
seeded as previously described198. After attachment, cells were washed twice with
1X phosphate buffered saline (PBS) and cultured in serum free DMEM for 24
hours. The media was then collected and centrifuged at 3000 RPM for 10 minutes
and the supernatant was collected in a fresh tube to be either used immediately or
stored in -80°C for future use.
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Cell Viability Assays
Cell viability was determined by MTT assays as described previously198. All the
MTT assays in this study were carried out at 72 hours post-treatment.
RNA Isolation and qRT-PCR
Total RNA was extracted from cells or tissue lysates by using TRIzol reagent
(Invitrogen, Carlsbad, USA) as previously discussed201. Complementary DNA
(cDNA) was synthesized using Verso-cDNA synthesis kit (Thermo fisher scientific,
MA, USA) or High-Capacity Reverse Transcription Kit (Applied Biosystems)
according to manufacturer’s protocol. qRT-PCR was performed using SYBR
Green master mix (Applied Biosystems, NY, USA). Beta actin was used an internal
control. Total RNA for RNA-seq analysis was isolated using RNAeasy columns
(Qiagen) as per manufacturer’s protocol. Relative gene expression analysis were
performed by utilizing ∆Ct method as described previously189.
Chromatin immunoprecipitation assay
Chromatin immunoprecipitation (ChIP) assay was performed as described
previously189. Briefly, chromatin immunoprecipitation was performed by utilizing
NFκB p65 along with IgG control. 3 µl purified chromatin for each reaction were
used for qPCR analysis. The threshold cycle (Ct), values obtained for each
genomic region were utilized for further analysis. For ChIP qPCR analysis, Ct
values were normalized to an input control and represented as a fold increase over
enrichment detected using IgG.
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Immunohistochemistry
Immunohistochemistry was performed as described previously201 We utilized
Novolink Polymer (Leica, Wetzlar, Germany), as per the manufacturer’s
instructions. Muscle sections prepared from human patient tissues were stained
with SIRT1 antibody (Cell Signaling Technology, Danvers, MA) and NOX4
antibody (Abcam, Cambridge, UK). Each muscle fiber in a cross-sectional field of
view was given an intensity score by evaluating staining intensity of positive
staining (0 = none, 1 = weak, 2 = intermediate, 3 = strong). The histoscore was
calculated by multiplying the percentage of fibers (0-100) with the particular score
by its corresponding intensity score (0-3). All the scores in a given section were
added, and the value was then divided by 100 to attain a score between 1 and 3.
Immunoblotting
Protein isolation and western blotting were performed as described previously [49].
Briefly, cells were washed twice with PBS and lysed in radio-immunoprecipitation
assay (RIPA) lysis buffer by incubating at 4°C shaker for 10 min. Then, the lysates
were centrifuged at 13000 rpm for 5 min and supernatant was collected. Protein
concentration was measured by Bradford assay. Equal amounts of protein were
used for western blotting. Primary antibodies against MuRF1, ATROGIN-1, p65
(NF-κB) (Santa Cruz Biotechnology, Dallas, Texas, USA), Sirt1, FoxO3a, FoxO1,
Acetyl-p65 (K310) (Cell Signaling Technology, Danvers, MA, USA), Tubulin and
Myosin heavy chain 2 (Developmental Studies Hybridoma Bank, Iowa City, IA) ,
Nox4 ( Abcam) were utilized for probing specific proteins.
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SIRT1 Activity Assay
SIRT1 activity was measured in myotubes by using Sirt1 activity assay kit following
manufacturer’s protocol (Sigma Aldrich CS1040). C2C12 myotubes were treated
with either control media, S2-013- orT3M4- conditioned media for 24 hours and
Sirt1 activity was measured.
NF-κB Reporter Assay
NF-κB luciferase adenovirus was purchased from Vector Biolabs (1740). C2C12
cells were seeded and differentiated in 6-wells plates as previously mentioned.
C2C12 myotubes were then treated with cancer-cell CM for 6 hours with and
without resveratrol. After 6 hours, cells were harvested and assayed for luciferase
activity using Promega Luciferase Reporter Assay according to manufacturer’s
instructions (#E1690).
Animal Studies
Orthotopic Studies: All the animal experiments performed in this study were
approved by University of Nebraska Medical Center Institutional Animal Care and
Use Committee (IACUC). Athymic female nude mice (NCr-nu/nu) were bred inhouse and 6–8-week-old mice were used for orthotopic implantations. 0.5 × 10 6
S2-013 scrambled control, S2-013 shSIRT1-A, or S2-013 shSIRT1-B cells were
injected into the pancreas of female athymic nude mice and 7 days postimplantation mice were segregated into groups of 10 animals each. Age and
gender-matched mice, without any tumor cell injection, were utilized as healthy
controls. Trans-resveratrol (Cayman Chemical, Ann Arbor, MI, Catalog #70675)
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was solubilized in 1.5% methylcellulose with vigorous vortexing202. Beginning on
day 7, mice received a daily oral treatment of 200mg/kg delivered using a 20G
gavage needle. Tumor volumes and body weights were recorded regularly. After
14 days of treatment, all the mice were euthanized and tumor weight, tumor
volume, gastrocnemius muscle weight, and body weight were measured. Tumor
tissue, liver, spleen, and muscles were flash frozen in liquid nitrogen and formalin
fixed for further analysis
For GKT studies, 0.25 X 106 S2-013 cells were implanted in the pancreas of
athymic nude mice. The mice were randomly divided into two groups. GKT137831
was solubilized in 1.2% of methylcellulose and 0.1% of polysorbate 80 and was
administered to 10 tumor-bearing mice at a concentration of 60 mg/kg via daily
oral gavage. The rest were administered the vehicle solution. To test for toxicity,
we also injected 4 healthy mice with GKT137831.
KPC tissues: The muscles of 10, 15 and 25 weeks of KrasLSL.G12D/+; p53R172H/+;
Pdx1-Cretg/+ (KPC) mouse spontaneous progression model of pancreatic cancer
were collected by euthanizing these mice along with littermate control.
Transgenic Mice Model: C57BL/6 Mice having Tamoxifen-inducible muscle
specific

CRE

was

obtained

from

Jackson

Laboratories

(Tg(ACTA1-

cre/Esr1*)2Kesr/J ; Stock No. 025750 ). Mice having Nox4 floxed were a kind gift
from Dr. Junichi Sadoshima (Rutgers). These mice were crossbred and genotyped
to get the desired mice genotype (Nox4 fl/fl: ACTA1-cre). Nox4 knockout was
induced in the muscle by administration of Tamoxifen for 5 consecutive days at a
concentration of 75 mg/kg as directed by Jackson laboratories.
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0.25 X 105 KPC 1245 cells were implanted in the pancreas of male age-matched
Nox4fl/fl: ACTA1-cre mice. Post-implantation, mice were segregated into two
groups of 8 mice each and one group was injected with tamoxifen to induce Nox4
deletion in the muscles.
Chemotherapy studies on Mice: Male C57/BL6 mice were treated with
FOLFIRINOX (100 mg/kg leucovorin, 5 mg/kg oxaliplatin, 50 mg/kg 5-fluorouracil,
and 50 mg/kg irinotecan) once a week via tail vein injection. Mice were treated with
gemcitabine at a concentration of 50 mg/kg twice a week via intraperitoneal
injection (IP). BMX-001 was injected via IP at a concentration of 0.5 mg/kg.
Mouse Body Fat Measurement
Fat percent in each mouse was measured by Dual-energy X-ray absorptiometry
(DEXA) scanning on the 18th day after implantation as previously mentioned203.
Mice were anesthetized using a mixture of isoflurane and oxygen and placed on
imaging positioning tray. Mice were scanned using a Lunar PIXImusTM
densitometer (GE Medical-Lunar, Madison, WI).
Measurement of Grip Strength
A grip strength meter (Columbus Instruments, OH, USA) was utilized to assess
forelimb grip strength as previously mentioned198. On the 18th day of treatment, we
acclimatized mice to the procedure room for 15 minutes and measured grip
strength as per manufacturer's instructions. We utilized the average value of three
measurements for analysis.
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Patient Samples
Skeletal muscle specimens were collected from pancreatic cancer patients under
UNMC Rapid Autopsy Program (RAP).
Detection of Reactive Oxygen Species in Muscles
Electron paramagnetic resonance spectroscopy was utilized to detect oxygen
radicals in the muscle tissues as previously described204. Briefly, gastrocnemius
muscle tissues were harvested and incubated for 1 h at 37°C with the cellpermeable O2˙−-sensitive spin probe 1-hydroxy-3-methoxycarbonyl-2,2,5,5tetramethylpyrrolidine (CMH, 200 μmol/l, Noxygen Science Transfer and
Diagnostics, Elzach, Germany) in a Krebs-HEPES buffer (pH 7.4) containing (in
mmol/l) 99 NaCl, 4.69 KCl, 2.5 CaCl2, 1.2 MgSO4, 25 NaHCO3, 1.03 KH2PO4, 5.6
d-glucose, 20 HEPES, and supplemented with the metal chelators DETC (5 μM)
and deferoxamine (25 μM). The EPR-CMH spectra was normalized to the
gastrocnemius muscle weight.
ROS Assay
Reactive oxygen species in cells were determined as described previously205. ROS
levels were determined by using oxidation-sensitive fluorescent dye 2′,7′–
dichlorofluorescin diacetate (DCFDA). C2C12 cells were seeded at 3.0 × 104 cells
per well in a clear bottom black 96-well plate. The C2C12 myotubes were then
differentiated and treated with the conditioned media for 8 hours. The media was
replaced with fresh DMEM containing 20 μM DCFDA. H2O2 along with DCFDA was
used as a positive control and 2′,7′-Bis(2-carboxyethyl)-5(6)-carboxyfluorescein
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was used as a negative control. Control, and treated cells were incubated at 37°C
for 30 min. The cells were washed with PBS and 100 μL of PBS was added to the
wells for measuring the emission of DCFDA using a Biotek Cytation 3 plate reader
(BioTek Instruments Inc, Winooski, Vermont). DCFDA fluorescence was
measured at 485 nm excitation wavelength and 529 nm emission wavelength.
Glucose Uptake Assay
Glucose uptake assay was performed as previously described 205. Briefly, S2-013
and T3M4 cells were seeded at a density of 5 x 104 cells/well in 12-well plates.
After overnight attachment, the cells were treated with resveratrol (25 µM) or Ex527 (0.5 µM) for 24 hours. The cells were then starved for 2 hours in DMEM without
glucose, glutamine, pyruvate, and fetal bovine serum. [3H]2-deoxy glucose was
then added to the wells, incubated for 20 minutes, washed once with 1X PBS and
then lysed with 1% SDS (sodium dodecyl sulfate). The lysates were then counted
for tritium incorporation by a scintillation counter, which was then normalized
according to cell counts. For C2C12 myotubes, glucose uptake was performed
after the differentiated myotubes were treated for 24 hours and normalization was
done using protein content.
RNA-seq Analysis
RNA sequencing was performed on myotubes treated with S2-013 CM with and
without resveratrol. All gene sets in GMT format with Entrez IDs for Mus musculus
were downloaded from http://ge-lab.org/gskb/. The gene set for TFactS
(http://www.tfacts.org/) was chosen from the list and was made into a separate file,
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converted

into

gene

symbols

through

ensembl

biomart

(https://www.ensembl.org/biomart), and predicted genes and pseudogene were
removed (n=10) before being used by GSEA2 v2.2.3 with 1000 permutations in
the classic scoring scheme. Heatmap of the normalized enrichment score was
produced in R v3.3.2 with the gplots package after filtering for the top 25% percent
most variable gene sets.
Patient Data
Our retrospective cohort study included all pancreatic cancer patients between
2009 and 2017 at University of Nebraska Medical Center, Omaha, Nebraska, USA
who were recipients of chemotherapy and underwent an abdominal CT scan at the
time of diagnosis and an interval scan at 8 weeks following chemotherapy. Prior to
exclusion, we had 1280 patients with a diagnosis of pancreatic cancer at our
institution. Exclusions included those who were treated at other institutions, those
who did not have a follow-up CT scan and those who did not receive
chemotherapy. After exclusion, we were left with a total of 162 patients.
The study was approved by the UNMC institutional review board. The UNMC
electronic data source, including patients electronic medical record (EMR), and the
cancer registry provided information on height, weight, disease stage, tumor
characteristics, demographics and cancer treatment including surgery type (no
surgery, pancreaticoduodenectomy or distal pancreatectomy) and the receipt of
chemotherapy and/or radiation. Height and weight were measured at a clinical visit
close to the CT scan performed at the time of diagnosis and at 8 weeks follow up.
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Body composition/CT image analysis of muscle mass
Abdominal CT scans at cancer diagnosis (prior to therapy initiation) and at 2-month
follow-up after treatment was retrieved from the picture archiving and
communication system (PACS) in our institution. Slice-O-Matic software version
5.0 (Tomovision) was used to calculate muscle mass by selecting a single CT slice
at the level of the third lumbar vertebrae (L3). Muscle mass was identified using
the Hounsfield unit threshold of −29 to +150 and measured as cross-section
surface area (cm2).
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Chapter 3: Role of Sirtuin 1 in Pancreatic Cancer
Cachexia
(Note – The data shown in this chapter has been submitted to a peer-reviewed journal
as of March 2019)

Introduction
Pancreatic cancer is the third leading cause of cancer-related deaths in the United
States206. It is predicted that by the year 2030, it will be the second leading cause
of cancer-related deaths207. The dismal five-year survival rate of pancreatic cancer
patients can be attributed to a variety of factors, including late diagnosis, early
metastasis, resistance to chemotherapy, and cachexia. Cachexia is a metabolic
syndrome that is observed in up to 80% of pancreatic cancer patients 208. One-third
of pancreatic cancer patients die due to cachexia-associated complications,
entailing respiratory or cardiac failure209. In pancreatic cancer patients, cachexia is
associated with poor response to chemotherapy and decreased overall
survival5,210.
Cachexia is defined as the loss in skeletal muscle mass that cannot be fully
reversed by conventional nutritional therapy and leads to progressive functional
impairment3. Until now, the manifestation of cancer cachexia has been attributed
to systemic inflammation caused by the host body and tumor-derived
cytokines208,211. Multiple clinical trials for combating cachexia with antiinflammatory agents have demonstrated unsatisfactory results 212. Currently there
are no FDA approved drugs to mitigate cancer-induced cachexia. Thus, there is
an urgent need to find more efficient therapeutic targets.
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Sirtuins are primarily NAD+-dependent protein deacetylases and mono[ADP-ribosyl] transferases213. They can sense energy fluctuations in the cells as
their enzymatic activity is dependent on using NAD+ as a cofactor. There are seven
mammalian sirtuins and they are also referred to as class III histone
deacetylases214. The cellular localization of the sirtuins varies. Some sirtuins are
present in the cytoplasm or the nucleus and the others in the mitochondria.
Mammalian sirtuins are involved in various functions such as chromatin regulation,
metabolic homeostasis, and cell survival under stress214.
It is now well-established that increased expression of muscle specific
ubiquitin ligases (MuRF1 and MAFbx/Atrogin) are a hallmark of muscle
atrophy215,216. These genes are activated by the FoxO family of transcription
factors217,218. Activities of FoxO1 and FoxO3 are regulated by cycles of acetylation
and deacetylation; the latter being mediated by a sirtuin family member SIRT1 219.
The role of SIRT1 in cancer is very ambiguous. It could act either as a tumor
suppressor or a tumor promoter, depending on its cellular context, and may have
different signaling targets in different cancer types220,221. In pancreatic cancer,
SIRT1-activating compounds (STACs) decrease tumor growth in vivo and in vitro
through a lysosome dependent pathway222. Sirtuins have also been illustrated to
play a role in muscle health223-225. To the best of our knowledge, the role of sirtuins
in pancreatic cancer cachexia has not yet been evaluated.
In this chapter, we elucidated the potential utility of targeting sirtuins in
combating pancreatic cancer cachexia. Moreover, we investigated whether
inhibition or activation of sirtuins in the muscle, irrespective of its effect in the tumor,
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would be sufficient to combat muscle wasting. Our findings demonstrate that
SIRT1 stabilization in the skeletal muscles can mitigate pancreatic cancer-induced
muscle wasting.
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Results
Expression of sirtuins in cachectic muscles
We evaluated the sirtuins that are altered in the pancreatic cancer-induced
cachectic muscle by determining the mRNA expression levels of all the seven
sirtuins in the gastrocnemius muscles from 10, 15, and 25-weeks-old KPC
spontaneous PDAC mice model and comparing them to the littermate controls.
Sirt1 expression was significantly decreased in gastrocnemius muscles from KPC
mice at 15 and 25 weeks of age, compared to that from the littermate controls
(Figure 7). However, we observed no significant alterations in the other sirtuins,
except for Sirt2, which was decreased in the KPC mice muscles only at 25-weeks
of age (Figure 8). Therefore, we continued our investigation on the role of Sirt1.
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Figure 7 : Sirt1 expression in KPC muscles. Sirt1 mRNA expression in KPC
mice gastrocnemius muscles (n=3) at 10, 15, and 25 weeks post birth. Data are
mean ± S.E.M., compared with t-test.; p**<0.01; p***<0.001
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Figure 8 : Expression of all sirtuins in KPC muscles. Sirtuin mRNA expression
in gastrocnemius muscles from KPC mice at 10, 15, and 25 weeks of age. Data
are mean ± S.E.M., compared with t-test. p*<0.05.
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We also wanted to evaluate if cachectic cancer patients had a similar decrease in
SIRT1 expression in skeletal muscles. For this purpose, we utilized muscle
sections from pancreatic cancer patients obtained from the Rapid Autopsy
Program at the University of Nebraska Medical Center. We observed decreased
muscle fiber cross-sectional area, along with a decrease in SIRT1 staining in
pancreatic cancer patient skeletal muscle sections (Figure 9A). We scored 54
patient muscle samples and observed a significant positive correlation between
muscle cross-section area and SIRT1 staining (Figure 9B, Table 2). We
investigated whether this phenotype was evident in other models of cancer
cachexia. We observed that muscles collected from C-26 colon tumor-bearing
mice also demonstrated a decrease in Sirt1 expression, with no significant
decrease in the other sirtuins (Figure 10).
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Figure 9 : Expression of SIRT1 in pancreatic cancer patients’ muscles. (A)
IHC staining of Sirt1 in skeletal muscles of pancreatic cancer patients were scored
according to the staining intensity. (B) Correlation of the average skeletal muscle
fiber cross-section area with the SIRT1 histoscore in 54 muscle autopsy samples
of pancreatic cancer patients. ‘R’ depicts Pearson’s correlation coefficient and p
value denotes the significance of the correlation.
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Table 2 : Patient characteristics for samples used for SIRT1 and Nox4 staining.

Age

Stage

Gender

Radiotherapy

Number

Frequency

40-49

2

3.7

50-59

9

16.7

60-69

25

46.3

70-79

13

24.1

80-89

4

7.4

90-100

1

1.9

I

2

3.7

IIA/B

9

16.7

III

3

5.6

IV

38

70.4

Unknown

2

3.7

F

15

27.8

M

39

72.2

No

30

55.6

Yes

19

35.2

Unknown

5

9.3
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Chemotherapy

None

3

5.6

FOLFIRINOX

3

5.6

Gemcitabine

17

31.5

Gemcitabine +

30

55.6

1

1.9

FOLFIRINOX
Unknown
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Figure 10 : Expression of Sirtuins in the C-26 model. Sirtuin mRNA expression
in gastrocnemius muscles from C26 tumor-bearing mice at day 21 post
implantation (n=5 in each group). Data are mean ± S.E.M., compared with t-test.
p*<0.05.
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In order to evaluate whether cancer cell-secreted factors could diminish Sirt1
expression in myotubes, we utilized the in vitro model of pancreatic cancer-induced
muscle atrophy. We treated C2C12 myotubes with CM from human (S2-013 and
T3M4) and mice (KPC 1245, 1199, and 242) pancreatic cancer cell lines. We
observed that the mRNA levels of Sirt1 decreased in C2C12 myotubes upon
treatment with human and mice PDAC cell line-CM (Figure 11A). We also
observed that expression of other sirtuins were not consistently altered (Figure
11B). Moreover, we also confirmed that the decreased expression correlated with
decreased Sirt1 activity in the C2C12 myotubes upon treatment with cancer cellCM (Figure 11C).
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Figure 11 : Expression of sirtuins in CM-induced muscle atrophy. (A) Sirt1
mRNA expression in myotubes treated with S2-013-, T3M4-, KPC 1245-, KPC
1199-, and KPC 242-conditioned media, (B) Sirt2-7 mRNA expression in myotubes
treated with S2-013-, T3M4-, KPC 1245-, KPC 1199- and KPC 242-CM for 24
hours. Data are mean ± S.E.M., compared with one-way ANOVA with Dunnett’s
multiple comparisons. p*<0.05; p**<0.01; p***<0.001. (C) Sirt1 activity in myotubes
treated with S2-013- and T3M4-CM for 24 hours. Data are mean ± S.E.M.,
compared with one-way ANOVA with Bonferroni’s multiple comparisons. p**<0.01;
p***<0.001.
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Since we observed a decrease in Sirt1, we hypothesized that stabilization of this
protein might lead to rescue of cancer induced muscle atrophy. Previous studies
have established that resveratrol (3,5,4’-trihydroxystilbene), a natural phytoalexin
and a polyphenol found in red wine increases the deacetylase activity of SIRT1 226.
It has also been shown to increase the expression of SIRT1227-229. Since we
observed that Sirt1 levels were decreased in cachectic muscles, we next
investigated the effect of resveratrol on the cachectic phenotype. Treatment with
cancer cell-CM and resveratrol (50 µM) rescued C2C12 myotube degeneration in
culture conditions, as measured by myotube thickness (Figure 12A, 12B). There
was also rescue of the cancer cell-CM-induced decrease in myosin heavy chain
expression. Resveratrol also diminished the cancer cell-CM-induced protein
expression of Atrogin-1 and MuRF1 muscle-specific ubiquitin ligases, which
mediate muscle breakdown (Figure 12C). The mRNA levels of MuRF1 (Trim63)
and Atrogin-1 (Fbxo32) were also decreased upon addition of resveratrol to the
CM (Figure 13). We also observed resveratrol-mediated rescue of Sirt1 mRNA
levels in the myotubes upon treatment with conditioned-medium (Figure 13). It is
important to mention that resveratrol did not alter the expression of other sirtuins
(Data not shown).
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Figure 12 : Resveratrol rescues CM-induced atrophy in C2C12 myotubes. (A)
Brightfield microscopy images (at 200x) of myotubes treated with S2-013-CM and
T3M4-CM with and without resveratrol (50 µM) treatment for 24 hours. Scale bars
represent 50 µm. (B) Myotube width was measured by ImageJ. Five
measurements were taken along the length of each myotube. (C) Immunoblots of
MyHC, Atrogin-1, and MuRF-1 in myotubes treated with S2-013- and T3M4-CM
along with resveratrol treatment for 24 hrs. Tubulin was used as a loading control.
Data are mean ± S.E.M., One-way ANOVA with Bonferroni’s multiple comparisons.
p*<0.05; p***<0.001.
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Figure 13 : Resveratrol decreases CM-induced increase in atrophy genes.
mRNA expression of Trim63 (MuRF-1), FBXO32 (Atrogin-1) and Sirt1 in myotubes
treated with S2-013- and T3M4-CM along with resveratrol (50 µM) for 24 hrs. Data
are mean ± S.E.M., One-way ANOVA with Bonferroni’s multiple comparisons.
p*<0.05; p***<0.001
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SIRT1 activation in pancreatic cancer cell lines leads to a decrease in
proliferation
Next, we wanted to investigate the efficacy of systemic modulation of Sirt1 in
diminishing muscle atrophy in mice. It was important to first evaluate the effect of
resveratrol on pancreatic cancer cell lines, so that we could delineate its effect on
muscles independent of its effect on tumor. Previous studies have demonstrated
that resveratrol decreases proliferation of some pancreatic cancer cells 230-232. We
wanted to determine if treatment of pancreatic cancer cell lines with resveratrol
would impact cell proliferation in our cell line models. Therefore, we treated S2013 and T3M4 cells with multiple doses of resveratrol. We observed that treatment
with resveratrol decreased cell proliferation in a dose-dependent manner (Figure
14A). Moreover, since pancreatic tumors have high rates of glycolysis 233, we also
evaluated whether resveratrol modified the glycolytic phenotype of pancreatic
cancer cells. We observed that resveratrol decreased glucose uptake in pancreatic
cancer cell lines (Figure 14B). We also observed that Ex-527, a SIRT1 inhibitor
that has previously been shown to increase tumor growth rates in vivo234,
increased glucose uptake in S2-013 and T3M4 PDAC cell lines (Figure 14C).
Resveratrol treatment also increased glucose uptake in myotubes treated with
cancer cell-CM (Figure 14D). These results demonstrated that resveratrol had an
adverse effect on tumor growth, but it also rescued glucose uptake in myotubes
which implies its role in reducing insulin resistance.
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Figure 14 : Effect of resveratrol on pancreatic cancer cells. (A) MTT assay
demonstrating the dose-dependent effect of resveratrol on S2-013 and T3M4 cell
survival 72 hours post treatment. (B) Relative glucose uptake in S2-013 and T3M4
cells upon resveratrol treatment (50 µM) for 24 hrs. (C) Glucose uptake in S2-013
and T3M4 cells upon Ex-527 (0.5 µM) treatment for 24 hrs. (D) Glucose uptake in
C2C12 myotubes upon treatment with cancer cell-conditioned media (CM) and
resveratrol for 24 hrs. Data are mean ± S.E.M., One-way ANOVA with Dunnett’s
(A), Bonferroni’s (D) multiple comparisons; Student’s t-test (B-C); p*<0.05;
p**<0.01; p***<0.001.
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To develop a model to test the effect of resveratrol on the muscle, independent of
its effect on the tumor, we generated SIRT1 knockdowns in S2-013 cells by
lentiviral-delivery of short hairpin RNA (shRNA) against SIRT1. Two constructs
targeting independent regions of SIRT1, shSIRT1-A and shSIRT1-B were used for
knocking down SIRT1 expression (Figure 15A). We then investigated whether
SIRT1 knockdown altered the sensitivity of cancer cells to resveratrol (25 µM) by
performing MTT assays. We observed that SIRT1 knockdown cells were less
sensitive to resveratrol (Figure 15B). Moreover, cancer cell-CM from the scrambled
control and the SIRT1 knockdown cell lines had similar effect on the protein
content of the myotubes, implying that modulation of SIRT1 in the tumor has no
impact on the cachectic potential in vitro (Figure 15C).
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Figure 15 : Effect of Resveratrol on Sirt1 knockdown pancreatic cancer cells
lines. (A) Immunoblot of SIRT1 in S2-013 cells. Tubulin was used as a loading
control. (B) Relative survival of S2-013 shScr, shSIRT1-A and shSIRT1-B upon
resveratrol treatment for 72 hours (25µM) by MTT assays. (C) Protein content in
myotubes treated with S2-013 shScr-CM, S2-013 shSIRT1-A-CM, S2-013
shSIRT1-B-CM along with resveratrol (50 µM). Data are mean ± S.E.M., Two-way
ANOVA with Bonferroni’s post-hoc analysis considering the interaction between
treatment and cell line (B), One-way ANOVA with Bonferroni’s multiple
comparisons (C), p*<0.05; p**<0.01; p***<0.001.
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independent of its effect on the tumor.
To extrapolate our findings, we evaluated whether stabilizing the expression of
Sirt1 in skeletal muscles by resveratrol would rescue muscle atrophy in animal
models. We implanted scrambled control and SIRT1 knockdown S2-013 cells
orthotopically into the pancreas of athymic nude mice and administered resveratrol
(200 mg/kg) daily by oral gavage, starting at 6 days post-implantation (Figure 16A).
We observed decreased tumor weight and volume upon necropsy in resveratroltreated scrambled control tumor-bearing mice but not in the SIRT1 knockdown
cells (Figure 16B, C). We also observed that resveratrol significantly diminished
the tumor-induced body weight loss in mice at day 21 post-implantation (Figure
17A).

74

Figure 16 : Resveratrol decreases growth of Sirt1 wildtype but not Sirt1 KD
tumors (A) Schematic illustration of the treatment strategy. (B-C) Post necropsy
measurements of S2-013 shScr (n=10), shSIRT1-A (n=10), and shSIRT1-B (n=10)
tumor weights (B) and tumor volumes (C). Data are mean ± S.E.M., One-way
ANOVA with Bonferroni’s multiple comparisons (B,C). p*<0.05; p**<0.01;
p***<0.001.
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Additionally, post-necropsy measurements demonstrated a significant rescue in
gastrocnemius muscle weight upon resveratrol treatment (Figure 17B). We
measured body fat percentage by performing DEXA scans at day 18 postimplantation and observed a significant increase in body fat percentage in tumorbearing mice upon resveratrol treatment (Figure 17C). There was also a significant
improvement in the forelimb grip strength of the mice cohorts treated with
resveratrol (Figure 17D). Quantification of the gastrocnemius muscle fiber crosssectional area in hematoxylin and eosin-stained tissue sections showed significant
increase in the mice treated with resveratrol (Figure 17E). There was an increased
expression of myosin heavy chain and decreased expression of MuRF1 and
Atrogin-1 in the gastrocnemius muscles of the mice treated with resveratrol (Figure
17F). Importantly, SIRT1 immunoblotting and IHC staining of gastrocnemius
muscle sections confirmed SIRT1 stabilization upon treatment with resveratrol
(Figure 17F and 18).
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Figure 17 : Resveratrol rescues muscle wasting in tumor-bearing mice. (A)
Change in body weight measurements of the tumor-bearing mice on day 21 post
implantation. (B) Post necropsy gastrocnemius muscle weight from S2-013 shScr,
S2-013 shSIRT1-A and S2-013 shSIRT1-B tumor-bearing mice. (C) Measurement
of fat percentage of S2-013 shScr (n=8), S2-013 shSIRT1-A (n=8) and S2-013
shSIRT1-B (n=8) tumor-bearing mice by DEXA scanning on day 18th post
implantation. (D) Measurement of grip strength of the tumor-bearing mice on day
18th post implantation. (E) Quantification of muscle fiber cross-sectional area in
hematoxylin and eosin-stained muscle sections from the tumor-bearing mice. (F)
Immunoblots of muscle tissue extracts from the tumor-bearing mice showing
regulation of MyHC, Atrogin, MuRF1, FoxO1, and FoxO3. Tubulin was used as a
loading control. Data are mean ± S.E.M., One-way ANOVA with Bonferroni’s
multiple comparisons ; p*<0.05;p***<0.001.
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Figure 18 : Resveratrol stabilizes SIRT1 in the gastrocnemius muscles of
tumor-bearing mice. SIRT1 staining in gastrocnemius muscles of healthy
controls and tumor-bearing mice treated with vehicle control or resveratrol.
Scales represent 250 µm.
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Resveratrol prevents muscle wasting by reducing ROS levels, and
diminishing the expression and activity of FOXO transcription factors
In order to investigate the potential mechanism of action of resveratrol-induced
protection against muscle wasting, we performed RNA-seq analysis on myotubes
treated with S2-013-CM with or without resveratrol for 24 hours. Since Sirt1 is
known to be involved in regulation of several transcription factors, we performed
Gene Set Enrichment Analysis (GSEA) and determined the enrichment for
transcription factors in the transcription factor gene set from TFactS
(http://www.tfacts.org/) to evaluate the significantly altered pathways in all the
cohorts (Figure 19A). We observed significant alterations in 9 out of 101
transcription factor pathways (Figure 19B). Interestingly, we observed enrichment
of FoxO1 and FoxO3 transcription factor-regulated genes in the myotubes treated
with S2-013-CM (Figure 19C). These set of genes also include Fbxo32 (Atrogin)
and Trim63 (MuRF-1) which are muscle-specific ubiquitin ligases65,66 responsible
for muscle atrophy. These enrichments were abolished by resveratrol treatment.
We validated the RNA-Seq results by evaluating the mRNA and protein levels of
FoxO1 and FoxO3 in myotubes treated with cancer cell-CM with or without
resveratrol. We observed that resveratrol decreased the cancer cell CM-induced
expression of the FoxO genes (Figure 19D). Similar results were observed in the
protein levels of FoxO1 and FoxO3 (Figure 19E), confirming that resveratrol
prevents muscle wasting by modulating FoxO proteins.
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Figure 19 : Resveratrol reverts cancer cell-CM-induced upregulation of FoxO
proteins via NF-κB. (A) Schematic illustration of the flow chart of RNA-Seq
analysis. (B) Heatmap showing the Z-score changes in the 3 comparisons. 9 out
of 101 pathways in the transcription factor database from TFactS were significantly
altered. (C) GSEA plots of FoxO1 and FoxO3. The normalized enrichment scores
(NES) for FoxO1 are 2.07 (CM-treated vs. control) and -1.9 (CM+Res-treated vs.
CM-treated) pathway. The NES for FoxO3 are 2.5 (CM-treated vs. control) and 1.6
(CM+Res-treated vs. CM-treated). (D) mRNA levels of Foxo1 and Foxo3 in
myotubes upon treatment with tumor cell-CM and resveratrol (50 µM). Data are
mean ± S.E.M., One-way ANOVA with Bonferroni’s multiple comparisons (D).
p*<0.05, p***<0.001.
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Next, we evaluated the potential direct relationship between Sirt1 expression and
muscle pathophysiology. For this purpose, we overexpressed Sirt1 by adenoviral
infection of myotubes after 48 hours of differentiation, and then treated them with
cancer cell-CM for 24 hours. Sirt1 overexpression attenuated the thinning of
myotubes induced by cancer cell-CM (Figure 20A). Consequently, Sirt1
overexpression also rescued the loss of protein content in myotubes upon CM
treatment (Figure 20B). Sirt1 overexpression also rescued the cancer CM-induced
decrease in myosin heavy chain expression levels. (Figure 20C). We also
observed a decrease in the mRNA levels of the FoxO1 and FoxO3 upon Sirt1
overexpression in CM-treated myotubes (Figure 21). Therefore, we concluded that
Sirt1 overexpression was sufficient to abolish the CM-induced expression of FoxO
proteins.
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Figure 20 : SIRT1 overexpression rescues atrophy in C2C12 myotubes. (A)
Brightfield microscopy images (at 200x), protein content analysis (B), protein lysate
immunoblot analysis (C) of GFP control or SIRT1 expressing myotubes, infected
adenovirally (Ad), upon treatment with tumor cell-CM for 24 hours. Scale bars
represent 75µm. Data are mean ± S.E.M., One-way ANOVA with Bonferroni’s
multiple comparisons (B). p*<0.05; p**<0.01.
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Figure 21 : SIRT1 regulates expression of FOXO proteins in C2C12
myotubes. Foxo1 and Foxo3 mRNA analysis (A) of GFP control or SIRT1
expressing myotubes, infected adenovirally (Ad), upon treatment with tumor cellCM for 24 hours. Data are mean ± S.E.M., One-way ANOVA with Bonferroni’s
multiple comparisons (A). p*<0.05; p**<0.01; p***<0.001.
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Additionally, the NF-B pathway, which has been shown to be a major player in
the development of cachexia235, was also significantly upregulated in myotubes
treated with S2-013-CM, and this increase too was abrogated by resveratrol
treatment (Figure 22A). These results are in line with previous studies
demonstrating the regulation of NF-κB activity by Sirt1-mediated deacetylation236238.

Moreover, a promoter-reporter assay with an NF-κB-responsive promoter-

luciferase reporter construct showed that resveratrol abolished the cancer cell-CM
induced NF-κB transcriptional activity in myotubes (Figure 22B). Previous studies
have demonstrated increased transcription activity of NF-κB upon acetylation of
p65 at lysine 310239. Since K310 residue of p65 has been known to be deacetylated
by SIRT1240, we evaluated K310 acetylation levels upon treatment of myotubes
with cancer cell-CM with and without resveratrol. We observed increased
acetylation of p65 upon cancer-cell CM treatment, and the effect was reduced by
resveratrol treatment (Figure 22C). In the next chapter, we will illustrate the
mechanisms via which NF-κB and FoxO pathways induce muscle wasting in
pancreatic cancer.
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Figure 22: Resveratrol rescues tumor-induced increase in NF-κB pathway.
(A) GSEA plots for NF-κB. NES for NF-κB are 2.91 (CM-treated vs. control) and
1.6 (CM+Res-treated vs. CM-treated). (B) Luciferase assay to measure NF-κBresponsive promoter-luciferase reporter activity upon treatment of myotubes with
cancer cell-CM with and without resveratrol (50 µM) for 6 hours. (C) Immunoblot
analysis of acetylated (taken at high and low exposures) and total p65 subunit of
NF-κB in myotubes treated with cancer cell-CM with and without resveratrol (50
µM) for 24 hours. Data are mean ± S.E.M., One-way ANOVA with Bonferroni’s
multiple comparisons (B). p*<0.05; p**<0.01; p***<0.001.
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Discussion
In our study, we concluded that SIRT1 stabilization in the muscles successfully
prevented muscle atrophy induced by pancreatic tumors in orthotopic mouse
models. Additionally, the loss of SIRT1 in skeletal muscles was consistent across
spontaneous progression models and human cancer patients. While, we did not
observe a consistent alteration in the expression levels of other sirtuins in the
cachectic muscles, we cannot rule out the roles played by other sirtuins in the
tumor cells. Multiple sirtuins have been shown to regulate aggressiveness in tumor
cells251,252 that may indirectly impart cachectic functions. Nonetheless, our studies
establish that stabilizing/increasing SIRT1 expression may provide therapeutic
opportunities for cancer cachexia.
Previous studies have demonstrated that resveratrol decreases tumor
growth in multiple myeloma, cervix carcinoma, and chronic myeloid leukemia253255.

While we observed similar anti-cancer response on pancreatic cancer cell lines

in culture and in orthotopic tumor models, we noted a direct effect of resveratrolmediated Sirt1 stabilization on preventing tumor-induced wasting in cultured
myotubes and in mice muscles. Additionally, we demonstrated that resveratrol can
abolish tumor-induced wasting in orthotopic models irrespective of its effects on
the tumor and has the potential to be utilized as a therapy for cachexia.
In our studies with the in-vitro models of cancer cell-CM-induced
myodegeneration, RNA-Seq analysis demonstrated NF-κB to be the most altered
pathway. This was in line with classical studies in cachexia that demonstrated NFκB to be the master regulator of ubiquitin proteasome in cancer-induced muscle
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atrophy235,256. Even though previous studies have demonstrated an association of
NF-κB activation and the proteins in the ubiquitin proteasome pathway 256,257, a
direct mechanism was still not known. We also observed tumor cell-induced
expression of FoxO proteins, which are known to be regulated by oxidative and
metabolic stress258. Based on the previous evidence highlighting the anti-oxidant
functions of resveratrol238 and the influence of oxidative stress on muscle
wasting259,260, we next asked if the decrease in muscle atrophy was due to altered
redox signaling via NF-κB activation. We observed that direct inhibition of NF-κB
was able to abolish the tumor cell-CM-induced expression of MuRF1 and Atrogin1 ubiquitin ligases that impart muscle wasting. Furthermore, we demonstrate that
resveratrol can inhibit tumor cell-CM-induced activation of NF-κB. Hence, we
establish that SIRT1 is an upstream regulator whose loss results in activation of
NF-κB, which contributes to muscle wasting.
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Chapter 4 : Role of Nox4 in Cancer-Induced Cachexia
(Note – The data shown in this chapter has been submitted to a peer-reviewed journal
as of March 2019)

Introduction
Reactive Oxygen Species (ROS) are highly unstable, reactive and short-lived
molecules which regulate signaling pathways in all cells, including skeletal muscle
cells241. The major types of reactive oxygen species found in cells are superoxide,
hydrogen peroxide and hydroxyl radical. At high concentrations, free radicals can
damage macromolecules and organelles, which thereby leads to tissue
degeneration or dysfunction84. Studies have established the role of high oxidative
stress or oxidative damage in the development of cancer-associated muscle
wasting and the rescue of such wasting when treated with antioxidants86. Similarly,
reports have also demonstrated induction of the ubiquitin proteasome pathway by
mild oxidative stress242. In this chapter, we investigated the role of oxidative stress
in the manifestation of pancreatic cancer cachexia. We evaluated the major
enzymes involved in ROS homeostasis and observed the key role of NADPH
oxidase 4 (Nox4) in the manifestation of cancer-cachexia. Nox enymes catalyze
the formation of free radicals by transferring an electron from NADPH to oxygen.
The mammalian Nox enzymes are Nox1 to Nox5, and Duox1 and Duox2 243(Figure
23). Among them, Nox4 is the only one which is constitutively active, with others
being activated by calcium or protein-protein interactions. This feature of Nox4 also
implies the relevance of evaluating the expression of Nox4 as compared to its
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activity, presumption being that any protein that is expressed is constitutively
active243. This chapter will illustrate the role of Nox4 in cachectic skeletal muscles
and its potential of being a therapeutic target. This chapter will also link the findings
of chapter 3 with the induction of oxidative stress in cachectic muscles.
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Figure 23 : Types of NADPH oxidases. “Nox family NADPH oxidases:
Molecular mechanisms of activation243 ”.
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Results
Resveratrol reduces ROS levels in cachectic muscles
Considering the established link between oxidative stress and muscle damage,
continuing with the data presented in chapter 3, we wanted to evaluate whether
reactive oxygen species (ROS) play a role downstream of Sirt1. On our advantage,
previous studies have established an inverse relationship between SIRT1 and
ROS levels in neuronal cells244. Hence, we investigated whether diminished SIRT1
levels in cachectic muscles contributed to oxidative damage, resulting in muscle
atrophy. We first tested our hypothesis in our in vitro model of cancer-induced
muscle atrophy. Interestingly, we observed increased ROS levels in the myotubes
treated with cancer cell-CM, which was abolished by resveratrol treatment (Figure
24).
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Figure 24 : Resveratrol decreases the tumor-induced ROS in C2C12
myotubes. ROS levels in C2C12 myotubes after treatment with cancer cell-CM
with or without resveratrol for 8 hours. Data are mean ± S.E.M., One-way ANOVA
with Bonferroni’s multiple comparisons, p*<0.05; p**<0.01; p***<0.001
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We next hypothesized that since ROS is increased in cachectic myotubes, there
would be an induction or reduction in the enzymes involved in ROS homeostasis.
To that end, we evaluated the levels of the key enzymes responsible for reactive
oxygen homeostasis in the muscles of the tumor-bearing mice treated with
resveratrol (Figure 25A, 25B and 26). Interestingly, we observed that mRNA levels
of NADPH oxidase 4 (Nox4) were increased in the muscles of the tumor-bearing
mice but downregulated upon treatment of the tumor-bearing mice with resveratrol,
implying its role in regulating oxidative stress in the cachectic muscles.
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Figure 25: Expression of ROS enzymes in the muscles of tumor-bearing
mice. (A)The mRNA levels of Nox4 in the gastrocnemius muscles from tumor cellimplanted mice (n=3 for each group) with and without resveratrol treatment. (B)
The mRNA levels of redox regulators in gastrocnemius muscles of tumor-bearing
mice with and without resveratrol treatment (n=3 for each group); Nox1-3 (NADPH
oxidase1-3), Sod1-2 (Superoxide Dismutase1-3). Data are mean ± S.E.M.,
compared with one-way ANOVA with Bonferroni’s multiple comparisons. p*<0.05;
p***<0.001.
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Figure 26 : Expression of ROS enzymes in gastrocnemius muscles in tumorbearing mice. The mRNA levels of redox regulators in gastrocnemius muscles of
tumor-bearing mice with and without resveratrol treatment (n=3 for each group);
Sod 3 (Superoxide Dismutase 3), Gpx1-4 (Glutathione peroxidase1-4), Catalase,
Trdxn1-3 (Thioredoxin1-3). Data are mean ± S.E.M., compared with one-way
ANOVA with Bonferroni’s multiple comparisons. p*<0.05.
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Keeping in mind our results from Chapter 3, that Sirt1 regulates NF-κB and FoxO,
we wanted to elucidate whether there was a redox link between the induction of
NF-κB and Nox4. Intrigingly, previous reports have demonstrated the regulation of
Nox4 by NF-κB245,246 in other models. To establish the direct regulation of Nox4 by
NF-κB in cachectic skeletal muscles, we performed ChIP assays. The ChIP assays
demonstrated increased occupancy of NF-κB (p65 subunit) at two consensus NFκB response elements in the promoter region of Nox4 in C2C12 myotubes upon
treatment with S2-013- and T3M4-CM. Moreover, the increased Nox4 promoter
occupancy of NF-κB in response to CM treatment was abrogated upon treatment
with resveratrol (Figure 27A). These results indicate that CM treatment facilitates
NF-κB activation and binding to Nox4 promoter, likely inducing the Nox4
expression; these events can be abolished by resveratrol treatment. To prove this
link via an independent method, we also utilized a cell permeable NF‐κB essential
modulator (NEMO)‐binding domain (NBD) peptide that can block the activation of
the IκB kinase (IKK) complex to inhibit NF-κB activity247. We observed abrogation
of the cancer cell-CM-induced expression of Nox4 and myotube atrophy by treating
the myotubes with NBD (Figure 27B and 27C). These results establish that in
cachectic muscles Nox4 expression is likely regulated by an increased activity of
NF-κB.
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Figure 27 : NF-κB regulates the expression of Nox4 in cachectic muscles. .
(A). ChIP analyses demonstrating distal (-1047) and proximal (-369) Nox4
promoter region occupancy by NF-κB. (B-C) Nox4, Trim63 and Fbxo32 mRNA
levels in C2C12 myotubes treated with cancer cell-CM and NBD. Data are mean
± S.E.M., One-way ANOVA with Bonferroni’s multiple comparisons. p*<0.05;
p**<0.01; p***<0.001.
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To validate our findings further, we wanted to evaluate the mRNA levels of Nox4
in the muscles from 10-, 15-, and 25-week-old KPC mice. We observed a
significant increase in Nox4 levels in the muscles of 25-week-old KPC mice (Figure
28A). Moreover, overexpression of NOX4 in C2C12 myotubes via adenovirus
infection directly led to myotube atrophy at 48 hours post-infection (Figure 28B),
implying a causative link between Nox4 expression and myotube atrophy. NOX4
overexpression also decreased the levels of myosin heavy chain in the myotubes
(Figure 28C). Additionally, we also observed that overexpression of NOX4 was
sufficient to increase the expression of FoxO genes (Figure 28D). These results
implied that FoxO is downstream of Nox4 induction.
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Figure 28 : Nox4 induces atrophy in cachectic muscles. (A) Nox4 mRNA levels
in KPC mice muscles at 10-,15- and 25-weeks of age (n=3). (B) Brightfield
microscopy images (at 200x) demonstrating thinning of C2C12 myotubes upon
Nox4 overexpression. Scale bars represent 250µm. (C) Immunoblot analysis of
Nox4 overexpressing myotube extracts depicting decrease in the levels of myosin
heavy chain. Tubulin was used as a loading control. (D) Foxo1 and Foxo3 mRNA
levels in C2C12 myotubes upon Nox4 overexpression for 48 hours. Data are mean
± S.E.M., compare to the control using Student’s t-test (A, D). p*<0.05; p***<0.001.
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Validating our findings in another model of cancer cachexia we found that muscles
from C26-bearing mice also demonstrated an increase in Nox4 and FoxO genes,
along with the induction of atrophy genes (Figure 29A,B). These results establish
the critical role of Nox4 in induction of the cachectic phenotype. We then wanted
to come back to our original premise that decreased Sirt1 led to Nox4 induction.
Consequently, overexpression of Sirt1 was sufficient in downregulating the
increased levels of Nox4 in the myotubes treated with cancer cell-CM (Figure 29C).
These results led us to hypothesize that Sirt1 downregulation leads to NF-κB
activation, which can lead to increased expression of Nox4, an inducer of oxidative
stress that can in turn induce the expression of the muscle-specific ubiquitin
ligases to facilitate myopathy (Figure 30).
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Figure 29 : Expression of atrophy genes in the muscles of C26-bearing mice.
(A-B) mRNA levels of Nox4, Foxo1, Foxo3, Trim63, and Fbxo32 in the
gastrocnemius muscles of healthy control and C26 bearing mice (n=5 in each
group). (C) Nox4 mRNA level in C2C12 myotubes upon treatment with cancer cellCM with or without adenoviral (Ad) expression of Sirt1. Data are mean ± S.E.M,
compared with Student’s t-test (A-B), One-way ANOVA with Bonferroni’s multiple
comparisons (C). p*<0.05; p**<0.01; p***<0.001.
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Figure 30 : Schematic illustration of the proposed pathway.
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We wanted to illustrate whether a simplistic flow of events could explain the entire
mechanism. To investigate this pathway further, we utilized, GKT137831 to inhibit
Nox4 activity248, BMX-001 to scavenge oxygen radicals249 and AS1842856 to
inhibit FoxO1 activity250 (Figure 30).We observed that MuRF1 (Trim63) and
Atrogin-1 (Fbxo32) were downregulated by targeting all the arms of the pathway
(Figure 31). We would like to mention that our proposed mechanism in no way
implies the absence of other branches and participants in the induction of cancer
cachexia.
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Figure 31 : Expression of atrophy genes upon treatment with inhibitors. The
mRNA levels of Trim63, Fbxo32 in C2C12 myotubes treated with control or cancer
cell-CM with, GKT137831 (10µM), AS1842856 (0.1µM), NBD (5µM), and BMX001 (1µM) for 24 hrs. Data are mean ± S.E.M., One-way ANOVA with Bonferroni’s
multiple comparisons, treated samples are compared to the non-treated samples.
p*<0.05; p**<0.01; p***<0.001,
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Nox4 expression in skeletal muscles drives cancer-induced cachexia
We next wanted to investigate whether Nox4 expression in muscles contributes to
cancer cachexia. For this purpose, we generated mice with tamoxifen-inducible
conditional knockout of Nox4 in the skeletal muscles (Nox4fl/fl; ACTA1-Cre/Esr1;
Figure 32A). We confirmed the muscle-specific Nox4 knockout after tamoxifen
injection in the gastrocnemius muscles via immunoblotting (Figure 32B).
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A.
B.

Figure 32 : Nox4 overexpression drives cachexia in orthotopic pancreatic
tumor models. (A) Schematic illustration of pancreatic cancer-cachexia model
utilizing Nox4fl/fl; ACTA1-cre/Esr1 mice. (B) Immunoblot analysis of muscle
extracts from control and Nox4 knockout mice depicting deletion of Nox4 in the
muscles. Actin was used as a loading control.
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Next, we orthotopically implanted mouse pancreatic cancer cell line (KPC 1245)
into the pancreas of Nox4fl/fl; ACTA1-Cre/Esr1 mice. We then randomly divided
the mice into two groups- to be injected with Tamoxifen (Nox4-KO) or solvent
control (Nox4-WT). Nox4 knockout in muscles significantly rescued tumor-induced
body weight loss, compared to the Nox4-WT mice (Figure 33A). Additionally, we
also observed that Nox4 knockout significantly rescued the tumor-induced loss in
forelimb grip strength (Figure 33B) and gastrocnemius muscle weight (Figure
33C), as compared to the Nox4-WT mice.
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A.

B.

C.

Figure 33 : Nox4 Knockout in muscles rescues atrophy in tumor-bearing
mice. (A) Change in body weight of mice after 21 days of implantation. (B) Grip
strength of tumor-bearing Nox4 WT and Nox4 knockout mice on the 18th day post
implantation. (C) Post necropsy gastrocnemius muscle weight of healthy control
(n=10), tumor-bearing Nox4 WT (n=8) and tumor-bearing Nox4 knockout (n=8)
mice. Data are mean ± S.E.M., One-way ANOVA with Bonferroni’s multiple
comparisons (A-C). p*<0.05; p**<0.01; p***<0.001.
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It is important to mention here that there was no significant difference in tumor
weights between the two groups (Figure 34A), implying that the changes in muscle,
body weight and muscle function were predominantly due to changes in muscle
physiology. Additionally, gastrocnemius muscle tissue sections stained with
hematoxylin and eosin stain demonstrated a decrease in the muscle fiber crosssectional area in the tumor-bearing mice, and these effects were rescued by
knocking out Nox4 in the muscles (Figure 34B).
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B.

Figure 34 : Nox4 knock out regulates muscle atrophy in tumor-bearing mice.
(A) Post-necropsy tumor weights from tumor-implanted Nox4 WT and Nox4 KO
mice. (B) Representative hematoxylin and eosin-stained muscle sections depicting
changes in the muscle fiber cross-sectional area. Scale bars represent 25µm.
Quantification of the gastrocnemius muscle cross-sectional area of healthy
controls and tumor-implanted mice (n=3). Data are mean ± S.E.M., One-way
ANOVA with Bonferroni’s multiple comparisons (B), Student’s t-test (A). p*<0.05;
p***<0.001.
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Next, we also evaluated the molecular markers in the muscles of the tumor-bearing
mice. We also observed that Nox4 knockout was able to rescue the decreased
myosin heavy chain levels in the tumor-bearing mice. Consequently, the tumorinduced increase in MuRF1 and ATROGIN-1 levels in the mice muscles was also
abolished by Nox4 knockout (Figure 35A). Interestingly, Nox4 knockout did not
have an impact on SIRT1 stabilization, implying the importance of targeting Nox4
independent of SIRT1 (Figure 35A). This might also imply Nox4 acting downstream
of Sirt1. Nox4 knockout also abrogated the tumor-induced mRNA levels of FoxO
transcription factors (Figure 35B). Therefore, these studies suggest that targeting
Nox4 in the skeletal muscles may combat cancer-induced cachexia.
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B.

Figure 35 : Nox4 regulates atrophy and FoxO genes in cachectic muscles.
(A) Immunoblot analysis of muscle extracts from healthy control, Nox4 WT and
Nox4 KO tumor-bearing mice. (B) Foxo1 and Foxo3 mRNA levels in
gastrocnemius muscles from control and tumor-implanted mice (n=5 for each
group). Data are mean ± S.E.M., One-way ANOVA with Bonferroni’s multiple
comparisons. p*<0.05.
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Pharmacological inhibition of Nox4 rescues cancer cachexia in mice models

For clinical relevance of this study, we wanted to target Nox4 pharmacologically.
We next investigated the potential of GKT137831 (henceforth referred to as GKT),
a NOX4/NOX1 inhibitor to rescue cachexia in pancreatic cancer mouse models.
This compound was our best option since it has already passed the Phase I safety
trial and is currently in Phase II for diabetes (NCT02010242) and primary biliary
cholangitis (NCT03226067). To evaluate the efficacy of GKT on cancer cachexia,
we implanted human pancreatic cell line S2-013 in 20 athymic nude mice and
randomly segregated them into two groups of 10 mice each. We started daily
treatment with GKT or vehicle control via oral gavage after 6 days postimplantation (Figure 36A). Three weeks after implantation, mice were sacrificed
and analyzed. We observed body weight loss in S2-013 tumor-bearing mice that
was rescued by treatment with GKT (Figure 36B). There was no difference in tumor
weight upon treatment with GKT, implying that these effects were muscle-specific
(Figure 36C).
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A.

B.

C.

Figure 36 : Pharmacological inhibition of Nox4 rescues muscle wasting in a
cancer cachexia model. (A) Schematic illustration of S2-013 tumor cell
implantation and GKT therapy initiation in athymic nude mice. (B) Change in the
mouse body weight at day 21 post implantation for healthy controls (n=9), healthy
controls with GKT (n=4), S2-013-implanted (n=9), and S2-013-implanted with GKT
treatment (n=10). (C) Post-necropsy tumor weight for S2-013-implanted mice with
and without GKT treatments. Data are mean ± S.E.M. One-way ANOVA with
Bonferroni’s multiple comparisons (B,C). p*<0.05; p***<0.001.
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We observed that GKT could rescue tumor-mediated decrease in gastrocnemius
muscle weight, body fat content, and grip strength (Figure 37A-C). We also
observed an increase in the reactive oxygen free radicals in the gastrocnemius
muscles of tumor-bearing mice by performing EPR spectroscopy; the increase was
abrogated by treatment with GKT (Figure 37D).
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Figure 37 : GKT rescues muscle wasting in tumor-bearing mice. (A)
Gastrocnemius muscles for S2-013-implanted mice with and without GKT
treatments. (B) Body fat percent at day 18 in tumor-bearing mice with and without
GKT treatments. (C) Grip strength measurements on day 18 post implantation. (D).
Gastrocnemius muscle ROS measurement by EPR in tumor-bearing mice with and
without GKT treatment (n=5 for each group). Data are mean ± S.E.M., One-way
ANOVA with Bonferroni’s multiple comparisons (A-D).p*<0.05; p**<0.01;
p***<0.001.
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GKT treatment also abrogated the tumor-induced decrease in gastrocnemius
muscle fiber cross-section area, as observed by performing tissue staining with
hematoxylin and eosin (Figure 38A). Analysis of molecular markers of atrophy by
immunoblotting demonstrated GKT-mediated rescue in the levels of myosin heavy
chain, ATROGIN-1 and MURF1 (Figure 38B). Moreover, SIRT1 levels were not
stabilized up to control levels upon GKT treatment, implying again that SIRT1 is
an upstream regulator of Nox4 (Figure 38B). GKT treatment also diminished the
tumor-induced mRNA expression of FoxO transcription factors (Figure 38C).
Therefore, we concluded that pharmacological inhibition of NOX4 in the PDAC
tumor models can combat muscle wasting.
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B.

C.

Figure 38 : GKT rescues muscle atrophy via FoxO pathway.
(A)
Representative images of hematoxylin and eosin-stained gastrocnemius muscle
cross-sections. Quantification of the cross-sectional area measured via ImageJ
(n=3). Scale bars represent 100µm. (B) Immunoblot analysis of gastrocnemius
muscle extracts from mice with indicted treatments. (C) FoxO1 and FoxO3 mRNA
levels in gastrocnemius muscles from mice with indicted treatments (n=3 for each
group). Data are mean ± S.E.M., One-way ANOVA with Bonferroni’s multiple
comparisons (A,C). p*<0.05; p**<0.01; p***<0.001.
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To validate whether this phenotype was clinically significant, we performed Nox4
staining on skeletal muscle tissue sections from human pancreatic cancer patients
obtained from the Rapid Autopsy Program and observed a significant negative
correlation between the muscle fiber cross-section area and staining intensity
(Figure 39A and 39B).

This demonstrated that cachectic patients have an

increased expression of Nox4 in their muscles.
We concluded our study by establishing the pathway illustrated in Figure 40 and
demonstrated the prevention of cachexia by inhibiting the key players of this
pathway.
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A.

B.

Figure 39 : Nox4 expression in human PDAC muscle samples. (A)
Representative images of NOX4-stained human muscle specimens. (B)
Correlation of Nox4 staining histoscore and muscle fiber cross-sectional area in
skeletal muscles from human pancreatic cancer patients (n=47).
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Figure 40 : Schematic illustration of the action of resveratrol and GKT as
potential therapeutic interventions in combating muscle wasting in cancer.
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Discussion
Since SIRT1 is a known regulator of oxidative stress244, we screened for the
redox regulators that were induced by cancer cell-CM. Our screening identified
Nox4 to be the key oxidative stress regulator that was upregulated in the muscles
of tumor-bearing mice, an effect that was abrogated by resveratrol treatment.
Notably, Nox4 is also demonstrated to be upregulated in angiotensin II-induced
muscle wasting, implying the possibility of a common pathway261 in multiple muscle
disorders. Moreover, NOX4 expression also demonstrated to have a significant
negative correlation with the skeletal muscle fiber cross-sectional area in human
pancreatic cancer patients. Previous studies have demonstrated that Nox4 is
regulated by NF-κB in different models245,246. Herein, we demonstrate that Nox4
promoter occupancy by NF-κB and NF-κB activity are significantly induced by
tumor cell-CM, and the effect is abrogated by resveratrol. Furthermore, musclespecific Nox4 knockout and pharmacological blockade of Nox4 in tumor-bearing
mice abolished tumor-induced muscle atrophy. We also observed a decrease in
the expression of Nox4-induced FoxO expression. These studies demonstrate that
SIRT1 regulates oxidative stress and atrophy in skeletal muscles by NF-κBmediated expression of FoxO. Interestingly, GKT137831, a Nox1/Nox4 inhibitor,
which is in clinical trials for various diseases, can potentially be utilized in a muscle
wasting syndrome.
Overall, this study demonstrates that tumor-induced muscle wasting was
mediated by the SIRT1 loss-triggered activation of NF-κB, which in turn induces
the expression of Nox4 in skeletal muscles, leading to induction of the protein
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degradation pathways. These findings provide new insights into the mechanisms
that underlie weight and muscle loss in cancer cachexia. These studies also
provide novel therapeutic opportunities for targeting tumor-induced skeletal
muscle wasting.
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Chapter 5: Role of Oxidative Stress in ChemotherapyInduced Muscle Atrophy in Pancreatic Cancer
(Note- The data in this chapter is under preparation to be submitted to a peer-reviewed
journal as of March 2019)

Introduction

Cancer-associated cachexia limits cancer therapy, quality of life and survival209,210.
In 2011, the international consensus defined cancer cachexia as a multifactorial
syndrome with ongoing loss of skeletal muscle mass, with or without loss of fat
mass. This weight loss cannot be fully reversed by conventional nutritional support
and leads to progressive functional impairment3. To update the definition of
cachexia, Vagnildhaug et al. have recently established a weight loss grading
system (WLGS) which is related to survival and progression of the disease in
cancer patients262. This grading system considered the body mass index (BMI) and
the degree of weight loss of the patient and is now included in the international
practice guidelines of the European Society for Clinical Nutrition and Metabolism
(ESPEN). However, even though BMI has been demonstrated to play a role in
determining the prognosis of the patient, studies have also established skeletal
muscle mass loss as a negative prognostic factor, regardless of overall body
weight263. Onesti et al. (2016) have found sarcopenia to be a predictor of overall
survival (OS) in male patients undergoing pancreatic resection 264. Similarly, a
study conducted in Japan by Ninomiya et al. (2017) showed sarcopenia to be a
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valid prognostic factor as tumor size and resection margins in patients undergoing
surgical resection for pancreatic ductal adenocarcinoma7.
Additionally, studies have also demonstrated that chemotherapy alone can
induce muscle wasting in experimental mice models265. In 2016, Baretto et al. also
reported that cancer and chemotherapy contribute to weight loss by activating the
same pathways in colon tumor-bearing mice models. These pathways included
mitochondrial dysfunction, alteration in the TCA cycle, fatty acid metabolism and
modification of reactive oxygen species, to name a few176. These studies have
shed light on the importance of elucidating the mechanism of chemotherapyinduced muscle wasting.
The goal of our study was to determine the correlation between skeletal
muscle depletion and survival outcomes in patients with pancreatic cancer. Since
our patient cohort was either treated with gemcitabine or FOLFIRINOX, we wanted
to evaluate the effect of these chemotherapeutic agents on body weight loss and
muscle wasting in an experimental murine model. Moreover, we also wanted to
elucidate the pathway which leads to muscle wasting and attempt to combat the
wasting via pharmacological intervention.
Since chemotherapy has been demonstrated to increase ROS in cancer
cells266 in its process to abolish it, we hypothesized that chemotherapy would be
increasing ROS in other tissues, including skeletal muscles. In this chapter, we will
illustrate our findings on the and the role of oxidative stress in chemotherapyinduced skeletal muscle wasting.
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Results
Muscle-loss correlates negatively with survival in pancreatic cancer
patients after therapy
We collected the clinical data for the patients at two separate time points: at
diagnosis and at eight weeks after the start of therapy. At the same timepoints
calculation of the muscle mass value was performed for each patient using the
Slice-O-Matic software (Figure 41A). We subdivided the patients into three groups
based on the degree of muscle loss at 8 weeks compared to the time of diagnosis.
Majority of the patients (57%) had less than 10% muscle loss or had muscle gain,
twenty-nine percent had 10-20% muscle loss, and the remaining fourteen percent
had muscle loss that was greater than 20%. Kaplan-Meier curves demonstrate that
patients with continuous muscle loss during the first eight weeks of therapy have
inferior PFS (p-value = 0.027), Figure 1, and OS (the p-value = 0.038). Adjusting
for a list of confounders, the p-value is 0.038, indicating a significant risk of death
associated with higher percentage of muscle loss. (Figure 41B).

126
A.

Before Treatment

After Treatment

B.

C.
Overall Survival and muscle change

Progression Free Survival and muscle change
1.00

Function
Survival Distribution
Survival Distribution Function

Function
Distribution
SurvivalSurvival
Distribution Function

1.00

0.75

0.50

0.25

0.00
0

10

20

30

40

50

60

70

80

90

0.75

0.50

0.25

0.00
0

10

20

30

OS_month
STRATA:

mus_ch_cat=<10% loss
mus_ch_cat=>=10% loss
mus_ch_cat=>=20% loss

40

50

60

PFS_month
Censored mus_ch_cat=<10% loss
Censored mus_ch_cat=>=10% loss
Censored mus_ch_cat=>=20% loss

STRATA:

mus_ch_cat=<10% loss
mus_ch_cat=>=10% loss
mus_ch_cat=>=20% loss

Censored mus_ch_cat=<10% loss
Censored mus_ch_cat=>=10% loss

Figure 41 : Muscle loss in Pancreatic Cancer Patients leads to poor
prognosis. (A) Representative images of abdominal muscles around the L3
lumbar vertebrae before and after 8 weeks of chemotherapy. (B-C) Overall and
Progression Free Survival curves.
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Table 3 : Patient characteristics for L3 muscle measurement.

Demographic
Age median 63.5 (32-87
years)
Gender M
F
Stage I-II
III
IV
Rx
Gemcitabine
FOLFIRINOX
Others
None
Resection Yes
Muscle loss <10%
>10%
BMI
<10%
>10%

Frequency (N=162)

Frequency percent (%)

100
62
41
44
77
74
82
4
2
56

61.73
38.27
25.31
27.16
47.53
45.68
50.62
3.47
1.23
34.57

90
67
128
34

57.32
42.68
79
21
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Effect of Chemotherapy on Muscle Mass and Function in Mice

To generate an experimental model to study the effect of chemotherapy on
muscles, we treated normal mice with Gemcitabine or FOLFIRINOX for a period
of 8 weeks (Figure 42A). The doses of gemcitabine and FOLFIRINOX were similar
to those used in experimental cancer models201,267. We observed a decrease in
body weight, grip strength and rotarod performance upon treatment with
chemotherapy (Figure 42B-D).
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A.

B.

C.
D.

Figure 42 : Chemotherapy induces loss in body weight and muscle function
in mice. (A) Schematic illustration of treatment of C57/BL6 with gemcitabine
(n=12) and FOLFIRINOX (n=12). (B) Measurement of change in body weight after
8 weeks of chemotherapy treatment; control (n=6), gemcitabine (n=12),
FOLFIRINOX (n=12). (C) Change in Grip Strength of control, gemcitabine-,
FOLFIRINOX- treated mice. (D) Change in Rotarod Performance of control,
gemcitabine-, FOLFIRINOX-treated mice. Data are mean ± S.E.M. One-way
ANOVA was performed and Tukey’s post-hoc analysis was performed to compare
all the groups. p<0.001 is indicated as *** to compare gemcitabine and
FOLFIRINOX with the control group.
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Post-necropsy measurements of gastrocnemius muscles depicted a decrease in
muscle weight (Figure 43A). As mentioned in chapters 3 and 4, muscle wasting is
characterized by the increase in muscle specific ubiquitin ligases, MuRF1 and
Atrogin-1, which are responsible for the protein turn over in muscles 215,216.
Therefore, we also measured the mRNA levels of these two genes in the muscles
of the mice treated with chemotherapy. We observed an increase in the ubiquitin
ligase expression implying an increase in protein ubiquitination in the muscles
(Figure 43B-C).
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A.

B.

C.

Figure 43 : Chemotherapy induces muscle atrophy in mice. (A) Post-necropsy
measurement of gastrocnemius muscle of control (n=6), gemcitabine- (n=12),
FOLFIRINOX (n=12)- treated mice. (B-C) mRNA expression of Trim63 (MuRF1)
and Fbxo32 (Atrogin-1) in gastrocnemius muscles of control (n=3), gemcitabine(n=3), FOLFIRINOX- (n=3) treated mice. Data are mean ± S.E.M. One-way
ANOVA was performed and Tukey’s post-hoc analysis was performed to compare
all the groups (A), Student’s t-test (B-C) was performed. p<0.05 is indicated as *,
p<0.01 as **, p<0.001 as ***.
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As previously mentioned, studies have demonstrated modification in ROS
pathways upon treatment with chemotherapy such as FOLFIRI176. We wanted to
evaluate whether similar pathways were also activated upon treatment with
gemcitabine and FOLFIRINOX. To this end, we measured the levels of reactive
oxygen species in the gastrocnemius muscles via Electron Paramagnetic
Resonance (EPR) by utilizing a superoxide-sensitive probe as demonstrated in
previous studies268. We observed a significant increase in ROS in the muscles of
the mice treated with chemotherapy (Figure 44).
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A.

B.

Figure 44 : Chemotherapy induces ROS in gastrocnemius muscles in mice.
EPR measurement of gastrocnemius muscle of control (n=5), gemcitabine- (n =5),
FOLFIRINOX (n =5)-treated mice. Data are mean ± S.E.M. Student’s t-test was
performed. p<0.05 is indicated as *, p<0.01 as **.
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Pharmacological blockade of oxidative stress rescues chemotherapyinduced muscle wasting

To combat the increased levels of ROS in the muscles of the chemotherapytreated mice, we utilized a superoxide dismutase mimetic, BMX-001 (hereafter
termed as BMX). This drug acts as a mimic of SOD and is present in the nucleus,
mitochondria, cytoplasm and the extracellular matrix269. This compound has been
approved by the FDA270 and is now currently in clinical trials for high grade glioma
(NCT02655601), head and neck cancer (NCT03386500), multiple brain
metastasis (NCT03608020) primarily as a radio-protectant. After two weeks of
treatment with chemotherapy, mice were divided into two groups, and one group
(n=5) was given BMX and the other vehicle control (n=5) (Figure 45A). We
observed that the decrease in body weight, grip strength and rotarod performance
was rescued in mice treated with BMX along with chemotherapy (Figure 45B, 46
A-D).
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B.

Figure 45 : Pharmacological blockade of ROS rescues chemotherapyinduced body weight loss and muscle function. Schematic illustration of
treatment of C57/BL6 with Gemcitabine (n=10) and FOLFIRINOX (n=10). After two
rounds of chemotherapy, 5 mice in each group were treated with BMX-001. (B)
Measurement of change in body weight after 8 weeks of chemotherapy treatment;
control (n=10), gemcitabine- (n=5), gemcitabine and BMX- (n=5), FOLFIRINOX(n=5), FOLFIRINOX and BMX- (n=5) treated mice. Data are mean ± S.E.M. Oneway ANOVA was performed and Tukey’s post-hoc analysis was performed to
compare all the groups. p<0.01 as **.
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A.

C.

B.

D.

Figure 46 : BMX rescues chemotherapy-induced muscle wasting. (A) Change
in Rotarod Performance of control, gemcitabine-, gemcitabine and BMX-treated
mice (B) Change in Grip Strength of control, gemcitabine-, gemcitabine and BMXtreated mice. (C) Change in Rotarod Performance of control, FOLFIRINOX-,
FOLFIRINOX and BMX-treated mice. (D) Change in Grip Strength of control,
FOLFIRINOX-, FOLFIRINOX and BMX-treated mice. Data are mean ± S.E.M Oneway ANOVA was performed and Tukey’s post-hoc analysis was performed to
compare all the groups. p<0.05 is indicated as *, p<0.01 as **, p<0.001 as ***.
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We observed a rescue in gastrocnemius muscle weight upon treatment with BMX
and chemotherapy (Figure 47A). Hemotoxylin and Eosin (H&E) staining of
gastrocnemius muscle sections demonstrated decrease in cross sectional area
with chemotherapy which was rescued upon treatment with BMX (Figure 47B).
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A.

B.

Figure 47 : BMX rescues chemotherapy-induced muscle atrophy. (A) Postnecropsy measurement of gastrocnemius muscle of control (n=10), FOLFIRINOX(n=5), FOLFIRINOX and BMX treated (n=5)- treated mice. (B) Representative
images of H&E staining of gastrocnemius muscle sections of control (n=3),
FOLFIRINOX-(n=3), FOLFIRINOX and BMX- (n=3), gemcitabine- (n=3),
gemcitabine and BMX- (n=3) treated mice. Quantification of gastrocnemius muscle
cross sections. Data are mean ± S.E. One-way ANOVA was performed and
Tukey’s post-hoc analysis was performed to compare all the groups. p<0.05 is
indicated as *, p<0.001 as ***.
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The increase in MuRF1 and Atrogin-1 was abrogated with the use of BMX along
with chemotherapy (Figure 48A). Moreover, the EPR studies also demonstrated a
decrease in ROS in the muscles of the mice treated with BMX-001 along with
chemotherapy (Figure 48B). Therefore, we concluded that chemotherapy-induced
muscle wasting can be abrogated by scavenging reactive oxygen species in the
muscles.
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A.

B.

Figure 48 : BMX decreases chemotherapy-induced ROS in gastrocnemius
muscles. (A) mRNA expression of Trim63 (MuRF1) and FBXO3 (Atrogin-1) in
gastrocnemius muscles of control (n=3), FOLFIRINOX-(n=3), FOLFIRINOX and
BMX- (n=3), gemcitabine- (n=3), gemcitabine and BMX- (n=3) treated mice. (B)
EPR measurement of gastrocnemius muscle of control (n=5), gemcitabine- (n =5),
gemcitabine and BMX, FOLFIRINOX (n =3)-, FOLFIRINOX and BMX- (n=5).
treated mice. Data are mean ± S.E.M. One-way ANOVA was performed and
Tukey’s post-hoc analysis was performed to compare all the groups. p<0.05 is
indicated as *, p<0.01 as **, p<0.001 as ***.
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Pharmacological Blockade of oxidative stress in tumor-bearing mice
rescues chemotherapy-induced muscle wasting
In order to have translational relevance, we wanted to investigate whether BMX
would be successful in rescuing chemotherapy-induced wasting in tumor-bearing
mice. We orthotopically implanted 40 C57 mice with KPC 1245 cells. We then
randomly divided them into four groups of 10 mice. We injected one group with
FOLFIRINOX, second with BMX and the third with FOLFIRINOX and BMX. We
compared all these groups to the untreated tumor-bearing group. We started the
BMX treatment at the same time as FOLFIRINOX, after 4 days of tumorimplantation. Unfortunately, this study did not show us the expected results and
there was no rescue in body weight or muscle loss with BMX in the tumor-bearing
mice treated with FOLFIRINOX (data not shown). We re-evaluated our treatment
strategy and designed another one according to the ongoing clinical trials. We
pretreated the mice twice with double dose (1mg/kg) of BMX, 4 days and 2 days
before the start of the chemotherapy. FOLFIRINOX injections started from 4 days
post implantation. 21 days-post implantation, we observed a significant rescue with
BMX in body weight of the tumor-bearing mice which were treated with
FOLFIRINOX (Figure 49). We also observed that FOLFIRINOX treatment of
tumor-bearing mice caused more weight loss than just tumor-bearing mice,
confirming our hypothesis that chemotherapy exacerbates cancer induced muscle
wasting.
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Figure 49: BMX rescues chemotherapy-induced wasting in tumor-bearing
mice. Change in body weight of healthy control (n=8), KPC tumor-bearing (n=10),
KPC tumor-bearing treated with FOLFIRINOX (n=10), KPC tumor-bearing treated
with BMX (n=10), KPC tumor-bearing treated with FOLFIRINOX and BMX (n=10).
Data are mean ± S.E.M One-way ANOVA was performed and Bonferroni’s posthoc analysis was performed to compare all the groups. p<0.05 is indicated as *,
p<0.01 as **, p<0.001 as ***.
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On the 18th day-post implantation, we recorded the grip strength and latency to fall
of the mice. We observed that FOLFIRINOX treatment of the tumor-bearing mice
did not decrease the grip strength of the mice significantly as that compared to
untreated tumor-bearing mice. However, the decrease in grip strength was
rescued by BMX (Figure 50A). On the other hand, latency to fall showed a trend
to decrease in tumor-bearing mice treated with FOLFIRINOX as compared to the
untreated group. This decreased was rescued by BMX treatment (Figure 50B).
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Figure 50 : BMX rescues muscle function in chemotherapy-induced cachexia
in tumor-bearing mice. Decrease in grip strength (A), rotarod performance (B) of
healthy control (n=8), KPC tumor-bearing (n=10), KPC tumor-bearing treated with
FOLFIRINOX (n=10), KPC tumor-bearing treated with BMX (n=10), KPC tumorbearing treated with FOLFIRINOX and BMX (n=10). Data are mean ± S.E.M Oneway ANOVA was performed and Bonferroni’s post-hoc analysis was performed to
compare all the groups. p<0.05 is indicated as *, p<0.01 as **.
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Post-necropsy measurements demonstrated decrease in muscle weight of tumorbearing mice treated with FOLFIRNOX compared to the untreated group. This
decrease in muscle weight was rescued by BMX treatment (Figure 51A). It is
worthwhile to mention that the tumor burden was significantly decreased in the
group treated with FOLFIRINOX and BMX (Figure 51B). Therefore, we cannot
conclude that the effect of BMX is strictly due to its effect on the muscles. However,
due to the lack of better models to study the effect of a compound on skeletal
muscle wasting independent of it effect on the tumor, we have to depend on the
results of this study. We were successful in addressing this in chapter 3 but in this
case, this is the best model available. We believe since BMX is not aggravating
the tumor, but in turn is working synergistically to shrink it, this compound might be
an effective therapeutic intervention to prevent chemotherapy related wasting.
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Figure 51 : BMX rescues chemotherapy-induced wasting in tumor-bearing
mice. Decrease in muscle weight (A) and tumor weight (B) of healthy control (n=5),
KPC tumor-bearing (n=5), KPC tumor-bearing treated with FOLFIRINOX (n=5),
KPC tumor-bearing treated with BMX (n=5), KPC tumor-bearing treated with
FOLFIRINOX and BMX (n=5). Data are mean ± S.E.M. One-way ANOVA was
performed and Bonferroni’s post-hoc analysis was performed to compare all the
groups. p<0.05 is indicated as *, p<0.01 as **, p<0.001 as ***.
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Upon evaluating the molecular markers, we observed an increase in the atrophy
genes (MuRF1 and Atrogin) in the muscles of the tumor-bearing mice and those
treated with FOLFIRINOX (Figure 52A and 52B). This increase in atrophy genes
was rescued upon treating with BMX. We also evaluated the reactive oxygen
species in the muscles of the mice via EPR and observed an increase in ROS in
the muscles of the tumor-bearing mice with FOLFIRINOX and a reduction in ROS
with BMX treatment (Figure 52C).
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A.

B.

C.

Figure 52 : BMX rescues chemotherapy-induced ROS in the muscles of
tumor-bearing mice. mRNA levels of Trim63 (A), Fbxo32 (B) and EPR
measurements (C) in the muscles of healthy control (n=5), KPC tumor-bearing
(n=5), KPC tumor-bearing treated with FOLFIRINOX (n=5), KPC tumor-bearing
treated with BMX (n=5), KPC tumor-bearing treated with FOLFIRINOX and BMX
(n=5). Data are mean ± S.E. One-way ANOVA was performed and Bonferroni’s
post-hoc analysis was performed to compare all the groups. p<0.05 is indicated as
*, p<0.01 as **, p<0.001 as ***.
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Discussion

FOLFIRINOX and gemcitabine are two first line therapies for pancreatic cancer
patients, which have significantly improved survival of patients 271,272. However,
studies have established that chemotherapy can induce muscle and body weight
loss in patients.
We measured the L3 muscle mass in pancreatic cancer patients at
diagnosis and after treatment and correlated this mass with overall and
progression free survival. We demonstrated that decreased muscle mass is highly
prevalent among patients with pancreatic cancer and outperforms BMI as a
prognostic indicator. Given the retrospective nature of our study, causal
relationships cannot be determined definitively, and unmeasured confounding is
possible. However, we tried to minimize this with our use of a well-characterized
data set and correcting for all known potentially significant confounders. Next,
selection bias may affect the results, as patients who did not have available CT
imaging at diagnosis and at the time of next restaging were excluded from analysis.
Lastly, while we use a data-driven approach to define cachexia at a single time
point based on survival outcomes, this approach has been widely used in many
studies with remarkably similar cut points for cachexia across various populations.
To the best of our knowledge, this is the largest study evaluating the prognostic
role of muscle wasting in pancreatic cancer patients with significant results.
Furthermore, our group wanted to evaluate the effect of chemotherapy
alone on muscle and body weight. Experimental mouse models helped us to
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demonstrate that FOLFIRINOX and gemcitabine induced body weight and muscle
weight loss via increasing oxidative stress in the muscles. We validated this finding
by inhibiting oxidative stress by utilizing a superoxide dismutase mimetic, BMX001. This compound was preferred as it is already in clinical trials as a radioprotector in cancer treatment. It is important to mention that though using an
antioxidant was sufficient to prevent chemotherapy-induced wasting in mice
muscles, studies have shown antioxidants to increase tumor growth in
experimental models273,274. Therefore, this observation validated our use of BMX001, which has been demonstrated to be a pro-oxidant in tumors while being
antioxidants in other tissues275-277. However, we observed that FOLFIRINOX did
not increase the ROS levels in the muscles above the level of just the tumorbearing mice. We, therefore hypothesized that there might be an increased
oxidative damage which was not measured in the snapshot of the EPR
measurement. This might be because EPR only measures free oxygen radicals
present in the tissues and not damage that has already taken place. For this
purpose, we are currently evaluating oxidative damage in the muscle tissues. We
observed that BMX was able to rescue FOLFIRINOX induced wasting in
pancreatic cancer models. Future studies are needed to demonstrate the effect of
similar compounds in cancer models, but we believe our study is the first to provide
understanding of the role of oxidative stress-mediated muscle wasting induced by
chemotherapy.
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Chapter 6: Discussion and Perspectives
Cachexia has been identified as a syndrome for centuries. Hippocrates had
eloquently described this syndrome, “The flesh is consumed and becomes
water…the shoulders, clavicles, chest and thighs melt away…the patient becomes
thin and dry…this illness is fatal.. [Regardless of cause] the treatment is similar;
but few survive…” Even though there has been evidence of this syndrome in the
medical literature for centuries, it has been shunned by the scientific community
as a symptom of the disease and not a disease itself. This idea has changed
immensely in the last couple of years wherein groups have demonstrated an
increase in survival rates in preclinical models just by preventing cachexia and not
decreasing the tumor burden. Our study adds to the increasing knowledge and
understanding of this field and establishes unexplored avenues, to make a
difference in combating this syndrome.
Our study revolved mainly around pancreatic cancer, since it is
characterized by a dismal rate of survival and poor quality of life. Even after
therapy, the five-year survival rate is one of the least amongst all cancers. The low
survival rate is attributed to late diagnosis and early metastasis. Moreover, this
dismal survival can also, in part, be attributed to cachexia since about 80% of
pancreatic cancer patients suffer from this syndrome 208. The diagnosis of muscle
wasting is a part of the manifestation of pancreatic cancer and studies have
attributed inflammatory cytokines released by the tumor and the host body to be
the main culprit behind muscle wasting. Based on this hypothesis, clinical trials
have been performed targeting inflammatory cytokine but without any significant
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success. This has led to a lot of curiosity and urgency in finding newer targets and
therapeutic interventions and each study tells us a little more about this devastating
syndrome.
Chapters 3 and 4 of this dissertation deal with investigating novel targets
other than the inflammatory pathways, which are involved in the induction of
cachexia. We focused on sirtuins because they are the switches between signaling
pathways and metabolic networks and have been shown to play a role under
energy modulations in the cell. Consequently, we did find a sirtuin, Sirt1, to be
altered in all our cachectic models. Upon further analysis, we found that one of its
downstream targets was NF-κB. This was again intriguing, since NF-κB is also
regulated via cytokines. But clinical trials using anti-inflammatory agents did not
show any success. This raises many questions - do other signaling pathways work
through the same axis as cytokines but have different downstream mechanistic
regulators? In that case, would it be necessary to target both arms of the pathway?
We would also like to mention here that we did not observe a consistent difference
in cytokine profiles in our models of cachexia as compared to the pancreatic
epithelial cells or non-cachectic pancreatic cancer (data not shown). This
observation also led us to speculate the validity of exploring inflammatory
pathways as a therapeutic intervention for cancer cachexia.
We followed the axis downstream from NF-κB hypothesizing the role of
ROS in induction of muscle atrophy. Subsequently, we found Nox4 to be
modulated in cachectic muscles. Nox4 is also found to be upregulated in other
disorders such as muscular dystrophy and hypertension. This led us to another
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question – if the presence of a tumor is not necessary for the induction of this
protein in the muscles, then can this phenotype be attributed to tumor-secreted
factors or if is this a common defense mechanism of the body against any kind of
disorder, inflammation or injury? Cachexia or muscle wasting is not only seen in
cancer but also in diseases such as heart failure, chronic obstructive pulmonary
disorder (COPD) and tuberculosis. All of these diseases lack an uncontrolled
growing mass of cells. Therefore, the question is what is the systemic assault
which is common amongst all these disorders that leads to the same phenotypic
appearance and sometimes, also the same markers such as upregulation of
Nox4? We hypothesize that the liver and the hypothalamus may be playing a role
in this process. As previously mentioned in the Introduction of this dissertation,
hepatic metabolism is closely linked to skeletal muscle metabolism and this might
be common factor in all the diseases. There are liver-associated CD68+
macrophages which might be playing a role as well. Another important player in
wasting is the hypothalamus, which has receptors for adipokines and is prone to
inflammation via cytokines278. It is possible that an inflamed hypothalamus elicits
its effects in a similar way in all these diseases. However, due to time constraints
we did not attempt to answer these questions.
The fifth chapter of this dissertation investigates the effect of chemotherapy
on body and muscle weight loss. We found that chemotherapy on its own has a
negative effect on body and muscle weight loss without the presence of a tumor.
This result was neither counterintuitive or surprising, since the chemotherapies
used to treat pancreatic cancer are extremely toxic agents. They are almost
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equivalent to being called the necessary evil in the context of cancer treatment.
These agents are known to increase ROS in the tumor cells in order to destroy
them, therefore we hypothesized the same pathway of degeneration in the muscle
cells. We did observe an increase in ROS in the muscles of the mice treated with
chemotherapy. Consequently, our rationale pointed to the same pathway as
described in chapter 4. Did we just unravel a common pathway via which both the
tumor and chemotherapy are inducing muscle atrophy? Yes, we observed Nox4
to be upregulated in these muscles too (Data not shown). We pursued it and
treated the mice with FOLFIRINOX and GKT, hoping to rescue the wasting similar
to the tumor-bearing mice. Unfortunately, GKT was unable to rescue
chemotherapy-induced cachexia. This might imply that though Nox4 is
upregulated in the muscles, it might not be one of the main regulators of ROS
induction. There might also be more confounders, such as compensation from
other enzymes or drug interactions. Next, we attempted to utilize BMX to rescue
chemotherapy induced wasting, the successful results of which, are discussed in
chapter 5. BMX also proved to be able to combat chemotherapy-induced cachexia
in tumor-bearing mice and might be a potential contender for clinical trials.
We would also like to mention that our studies focused mainly on skeletal
muscle wasting in cachexia. Although we did measure fat content via DEXA
scanning and post-necropsy adipose tissue weight, we did not investigate the
mechanisms leading to adipose tissue wasting. To assess muscle function, we
performed grip-strength and rotarod measurements. These are the gold-standard
measurements

for cachexia

studies.

Post-necropsy,

we

measured

the
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gastrocnemius muscles of the mice to assess muscle weight change. In future
studies, we plan to measure more of the muscle groups of the leg – the quadriceps,
external digitalis and the soleus. We utilized CT scans of patients to measure the
muscle mass around the L3 vertebrae, which is currently the most accurate
method of detecting loss of muscle mass. Similarly, we also plan to measure the
lean body mass of mice via Magnetic Resonance Imaging (MRI) for a more
accurate measurement of muscle mass.
Moreover, we focused on the mechanisms leading to protein degradation
in the cachectic muscles. There are also studies which focus on the role of muscle
stem cells in cancer-cachexia. It has been demonstrated that there is impaired
regeneration of muscle cells in cachectic muscles. Therefore, in addition to protein
degradation, the cachectic muscles possess the inability to regenerate the muscle
fibers. It would be interesting to study the role and expression of Sirt1 and Nox4 in
the muscle stem cells in the cachectic muscles. We could also determine the status
of muscle stem cells in our models and treatments and, investigate whether
oxidative stress plays a role in reprogramming the muscle stem cell fate.
The use of antioxidants has been controversial in the treatment of cancer
since it is shown to exacerbate the disease273,279. Therefore, it is not recommended
that any antioxidant be used to scavenge the ROS generated in the muscles due
to the tumor or chemotherapy. Interestingly, BMX-001 has been shown to act as
an antioxidant in normal tissues and as a pro-oxidant in tumor tissues (Data
generated by collaborators, not shown). We demonstrated that this compound was
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successful in attenuating the high levels of ROS in cachectic muscles. However,
we have not examined its effect on the oxidative state of the tumor.
Furthermore, our laboratory has observed distinct metabolic profiles in
cachectic and non-cachectic pancreatic cancer patients. We have already
demonstrated that SIRT1 and Nox4, two genes which can regulate various
metabolic homeostasis pathways, are differentially expression in cachectic and
non-cachectic PDAC patients. Studying the metabolomic profiles further can
reveal the metabolic cues which might be regulating Sirt1 and Nox4. Since, we
have access to patient samples of various stages, it would also be intriguing to
map the metabolic and the genomic profile of these patients and analyze the
pathways and genes, which give rise to this syndrome at various stages of cancer
progression.
Our studies with two different models of cancer and chemotherapy-induced
cachexia point towards a serious concern in cachexia research. The ongoing
research attempting to combat cachexia in preclinical models do not consider the
involvement of chemotherapy. Though these studies are important to elucidate the
pathways and mechanisms involved in the induction of cachexia, their translational
value cannot be truly assessed unless the effect of chemotherapy is also
considered. This is because it would be highly unlikely for patients to be treated
for cachexia and not for tumor burden.
There is still much to be done in the field of cancer cachexia. We have been
successful in establishing novel targets, such as SIRT1 and Nox4, in cancerinduced cachexia. It is also important to mention that our studies in the chapters 3
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and 4 established that the alterations in Sirt1 and Nox4 were the cause of the
syndrome and not the result of the tissue damage. This is because overexpressing
both these proteins rescued or degraded myotubes, respectively. We have also
illustrated the role of oxidative stress in the induction of chemotherapy-induced
cachexia which can be reverted with the use of BMX-001. The most promising
factor of our studies is that all our therapeutic interventions have already passed
the first phase of clinical trials and have been deemed safe for use. Our ongoing
studies include investigating the effect of tumor and chemotherapy on cardiac
muscle and function and, the role of post-translational modifications in cachectic
muscles. We continue to work towards the understanding and treatment of this
devastating syndrome.
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